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The Role of Ikaros in CD8+ T cell Biology
Abstract
Naive CD8+ T cells represent one of the most potent cells in immunity, as they can differentiate into
cytolytic T lymphocytes (CTLs) that lyses virally infected cells or tumor cells through the production of
IFN-g, TNF-a, Perforin and Granzyme B. Their ability to differentiate into highly potent CTLs needs to be a
tightly regulated process in order to prevent autoimmunity and disease. However, activation in the
absence of key support such as cytokine signals or CD4+ T cell help, or constant challenge with antigen
can result in hyporesponsiveness of CD8+ T cells and their failure to mount a robust immune response.
Interest has grown in studying the epigenetics of T cells, as chromatin accessibility of key cytokine and
lytic mediator loci can determine the ability of the T cell to respond to antigen. Identifying the
transcriptional regulators of naive CD8+ T cell differentiation and activation is key to learning how to
modulate the CD8+ T cell response. Ikaros is a chromatin-remodeling factor that has been identified to
regulate autocrine IL-2 production by and the differentiation program of CD4+ T cells in response to TCR
and CD28 signals. As CD8+ T cells make little IL-2 and are dependent on paracrine IL-2 or inflammatory
signals for their differentiation, we hypothesized that Ikaros could regulate naÃ¯ve CD8+ T cell
differentiation through restriction of autocrine IL-2 production. In this thesis, I demonstrate that naÃ¯ve
CD8+ T cells with only one copy of Ikaros can differentiate in vitro into cytolytic effectors with enhanced
effector function, and this results from increased autocrine IL-2 production. This enhanced effector
function also sparked an investigation into pre-clinical models of cellular immunotherapy for cancer, to
determine if the Ikzf1+/- CTLs had enhanced anti-tumor function. In conclusion, modulating Ikaros activity
represents a new approach to controlling naÃ¯ve CD8+ T cell differentiation and effector function.
Through being able to produce more autocrine IL-2, an Ikzf1+/- CD8+ T cell may not require paracrine IL-2
from CD4+ T cells and can possibly resist the "exhausted" CD8+ T cell effector state during chronic
antigen exposure. Thus, investigating Ikaros' role in CD8+ T cell biology will help to elucidate how this
chromatin remodeling factor can influence appropriate CD8+ T cells responses to self and foreign
antigen, and ensure against inappropriate immunopathology caused by activated CD8+ T cells.
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ABSTRACT	
  
THE ROLE OF IKAROS IN CD8+ T CELL BIOLOGY
Shaun O’Brien	
  
Andrew D. Wells
Naive CD8+ T cells represent one of the most potent cells in immunity, as they can differentiate
into cytolytic T lymphocytes (CTLs) that lyses virally infected cells or tumor cells through the
production of IFN-γ, TNF-α, Perforin and Granzyme B. Their ability to differentiate into highly
potent CTLs needs to be a tightly regulated process in order to prevent autoimmunity and
disease. However, activation in the absence of key support such as cytokine signals or CD4+ T
cell help, or constant challenge with antigen can result in hyporesponsiveness of CD8+ T cells
and their failure to mount a robust immune response. Interest has grown in studying the
epigenetics of T cells, as chromatin accessibility of key cytokine and lytic mediator loci can
determine the ability of the T cell to respond to antigen. Identifying the transcriptional regulators of
naive CD8+ T cell differentiation and activation is key to learning how to modulate the CD8+ T
cell response. Ikaros is a chromatin-remodeling factor that has been identified to regulate
autocrine IL-2 production by and the differentiation program of CD4+ T cells in response to TCR
and CD28 signals. As CD8+ T cells make little IL-2 and are dependent on paracrine IL-2 or
inflammatory signals for their differentiation, we hypothesized that Ikaros could regulate naïve
CD8+ T cell differentiation through restriction of autocrine IL-2 production. In this thesis, I
demonstrate that naïve CD8+ T cells with only one copy of Ikaros can differentiate in vitro into
cytolytic effectors with enhanced effector function, and this results from increased autocrine IL-2
production. This enhanced effector function also sparked an investigation into pre-clinical models
of cellular immunotherapy for cancer, to determine if the Ikzf1+/- CTLs had enhanced anti-tumor
function. In conclusion, modulating Ikaros activity represents a new approach to controlling naïve
CD8+ T cell differentiation and effector function. Through being able to produce more autocrine
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IL-2, an Ikzf1+/- CD8+ T cell may not require paracrine IL-2 from CD4+ T cells and can possibly
resist the “exhausted” CD8+ T cell effector state during chronic antigen exposure. Thus,
investigating Ikaros’ role in CD8+ T cell biology will help to elucidate how this chromatin
remodeling factor can influence appropriate CD8+ T cells responses to self and foreign antigen,
and ensure against inappropriate immunopathology caused by activated CD8+ T cells.
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INTRODUCTION
The development of a naive T cell from a lymphoid precursor and its subsequent activation in
response to antigen involves multiple gene expression checkpoints that are governed by key
transcriptional repressors and activators. The first step of T cell generation involves differentiation
from the pluripotent hematopoietic stem cells (HSCs) into common lymphoid precursors (CLPs).
The CLPs demarcate a key node in T cell development, as they express a distinct genetic
program that predisposes them toward the lymphoid fate-a distinct cell fate from the
granulocyte/macrophage precursors (GMPs) lineage. These CLPs give rise to T, B and NK cell
precursors, which eventually proceed through their subsequent development into mature
lymphocytes. T cell maturation occurs in the thymus, and this process involves distinct gene
expression to guide thymocytes through positive and negative selection for T cells that have the
appropriate level of avidity for foreign antigen. Upon release into the periphery, a naive T cell
responds to appropriate antigen presentation and activates a genetic program that leads to their
differentiation into effector and memory T cells. A review of the naïve T cell activation program
and its corresponding genetic control of the IL-2 locus will demonstrate the importance of these
epigenetic checkpoints in ensuring appropriate T cell activation and differentiation.

Naïve T cell activation
For appropriate naïve T cell activation, both naïve CD4+ and CD8+ T cells require
engagement of their T-cell receptor complex (TCR) with a peptide/MHC complex and their CD28
co-stimulatory molecule with a B7 ligand on an activated antigen presenting cell (APC). Naïve
CD4+ T cells only require these signals to differentiate into IL-2 producers (1), while naïve CD8+
T cells fail to produce much IL-2 following TCR and CD28 stimulation (2). Instead, the highly
potent CD8+ T cells require additional “Signal 3” Cytokines to ensure their appropriate
differentiation into cytotoxic lymphocytes (3). This creates a situation for naïve CD8+ T cells being
dependent on paracrine IL-2 from activated CD4+ T cells (“CD4 help”) for their continued
activation and expansion (4).
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In the context of naïve CD4+ T cells, engagement of the TCR and CD28 leads to signaling
cascades that promote the activation of the cell and epigenetic changes that led to appropriate
gene expression, such as IL-2. The promoter region of IL-2 contains multiple binding sites for
TCR and CD28 initiated transcription factors that form an enhancesome in the promoter region
and promote its production during T cell activation (5). TCR and CD28 signaling result in the
generation of the transcription factors NF-AT, AP-1, NF-κB and their presence on the IL-2
promoter along with the Oct family members can promote IL-2 transcription (5). TCR signaling
+2

results in the activation of the Ca signaling and the mitogen activating kinase (MAPK) pathways
(6). The former is responsible for the generation of the NF-AT, which translocates to the nucleus
and binds to the ARRE-1, ARRE-2 and NF-IL2B promoter regions of IL-2 locus (7, 8). The MAPK
pathway results in the generation of the c-Fos protein and upon appropriate CD28-mediated
activation of the Phosphoinositide-3 kinase (PI3K)/AKT/JNK pathway that results in c-Jun
production, can dimerize with c-Jun to form AP-1 (9). Besides driving c-Jun production, CD28 costimulation can also activate the PKC-φ pathway (6), which will result in the activation of the NKκB family members. AP-1 is viewed as a primary initiator of IL-2 gene transcription and binds
cooperatively with the other transcription factors at the ARRE-1, ARRE-2, NF-IL2B and the
CD28RR sites of the IL-2 promoter (7).
Additionally, as CD4+ T cells are a major source of IL-2 (10, 11), their release of IL-2 has to
be tightly regulated. This is observed when naïve CD4+ T cells are stimulated with self-antigen,
as production of IL-2 by self-reactive CD4+T cells could contribute to autoimmunity and disease
(12). As antigen presenting cells that present self-antigen are poorly activated and express few
B7 ligands, self-reactive CD4+ T cells that bind the TCR-MHC complex do so in the absence of
CD28-B7 ligation. Stimulation in the absence of CD28, results in a state of CD4+ T cell anergy as
the CD4+ T cells fail to produce IL-2 upon re-stimulation (13). This can be traced to the lack of
AP-1 and NK-κB, which are derived from CD28 co-stimulation. The anergized CD4+ T cells
demonstrate increased transcriptional activity of NF-AT to drive anergy-associated genes (14, 15)
(16). These cells that are re-stimulated with peptide-MHC complexes in the presence of B7
ligands, fail to produce IL-2, do not undergo clonal expansion and fail to provide paracrine IL-2 for
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CD8+ T cell activation. This regulation of IL-2 availability prevents the aberrant activation of
CD4+T cells towards self-antigen presentation, and ensures that any self-reactive CD8+ T cells
do not receive paracrine IL-2 in the periphery.
The IL-2 locus is also regulated by epigenetic mechanisms, to ensure its appropriate
activation. In quiescent CD4+ T cells, the IL-2 promoter is an inactive, but permissive chromatin
state (7). Upon CD4+ T cell activation, the IL-2 promoter becomes hyperacetylated (17-19) and
becomes demethylated at CpGs (17). In contrast, naïve CD8+ T cells fail to hyperacetylate the IL2 promoter following TCR and CD28 stimulation (20), again indicating a difference in their ability
to produce IL-2. Thus, epigenetic mechanisms are in place to ensure appropriate transcription of
the IL-2 gene by naïve CD4+ and CD8+ T cells.

IL-2 activity in a primary immune response
Upon appropriate TCR and CD28 co-stimulation in response to a foreign antigen, naive T
cells can produce IL-2 to support their survival, promote cell cycle progression and T cell
expansion. Naïve CD4+ T cells produce high amounts of autocrine IL-2 in comparison to naïve
activated CD8+ T cells (2, 21) and play a critical role in sustaining an immune response. In a tricellular model of activation, activated CD4+ T cells license dendritic cells via CD40L-CD40
engagement (22), and the activated dendritic cell up-regulates more B7 ligands and peptide-MHC
complexes. Engagement with a naïve CD8+ T cell forms the tri-cellular model, and the naïve
CD8+ T cell becomes exposed to the paracrine IL-2 produced by the activated CD4+ T cell (10,
11, 23). A different version of T cell activation holds that after licensing of a dendritic cell and
disengagement from the CD4+ T cell, that a DC up-regulates CD70 and ligates with CD27 (24)
on a naïve CD8+ T cell. This engagement results in increased autocrine IL-2 production that
ultimately acts during the priming phase to promote memory CD8+ T cell formation (25). While
the sources of IL-2 differ in these two models, it is still apparent that IL-2 is a critical factor during
a primary immune response. During the initial T cell expansion phase, IL-2 acts in a positive feed
forward loop with the high affinity IL-2Rα (CD25) (26, 27), that is expressed on activated CD4+
and Cd8+ T cells following antigen stimulation. This high affinity IL-2Rα complexes with the IL-
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2Rβ (CD122) and the common γ chain receptor (CD132) to form the IL-2 receptor on activated T
cells (28). The paracrine IL-2 during the primary immune response promotes increased CD25
expression on T cells, as depletion of CD4+ T cells and their paracrine IL-2 in a primary immune
response results in a failure of CD8+ T cells to up-regulate much CD25 (29). IL-2 leads to
signaling through the associated PI3K/Akt pathway (30) or the JAK/STAT5 pathway (31).
PI3K/AKT signaling can activate the mTOR pathway, which has been demonstrated to regulate
the balance of effector and memory CD8+ T cells through inducing the transcription factor T-Bet
(32). Prolonged STAT5 signaling can also bias the CD8+ T cells towards a short-lived effector
phenotype(33). IL-2 signaling is also connected to cell cycle progression (16), IFN-γ production
(34, 35) or up-regulation of key transcription factors such as Bcl-2 (1) or Eomes in T cells (36). IL2 can also regulate its production through the induction of the transcription factor Blimp-1 in T
cells, as Blimp-1 has been associated with reducing IL-2 production (37) and driving terminal
effector CD8+ T cell differentiation (38, 39).
The level of IL-2 during the primary immune response has to be finely tuned as too much IL-2
can result in activation induced cell death (AICD) (1) and results in ill-timed T cell death during the
critical expansion phase (4). Additionally, the presence of IL-2 during the priming phase of the
immune response has been demonstrated to influence both effector CD8+ T cell (33, 36, 40, 41)
and memory Cd8+ T cell formation (42-44). The provision of IL-2 during the contraction phase of
the immune response can also result in increased T cell numbers due to increased cell
proliferation and increased apoptosis resistance (4, 45). Thus, IL-2 availability needs to be tightly
regulated during an immune response to determine the appropriate amount of antigen
experienced T cells that persist.
Overall the availability of IL-2 during an immune response can influence the numbers of
activated CD4+ and CD8+ T cells and also control their duration and differentiation into effector
cells. As IL-2 transcription is influenced by multiple transcription factors from TCR and CD28mediated signaling cascades, it is important to identify transcriptional repressors that can
integrate TCR and CD28 signaling for the appropriate production of IL-2. These transcriptional
repressors can regulate IL-2 availability and prevent immunopathology, through ensuring that this
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critical cytokine for T cell activation and differentiation is released after receiving appropriate
antigen and B7-costimulatory signals.

Ikaros
One such factor is Ikaros (Ikzf1), a C2H2-motif zinc finger transcription factor that has 4 Nterm and two C-term zinc fingers (Fig. 1). There are 8 isoforms of Ikaros that are generated due
to alternative splicing, and Ik1 and Ik2 are the predominant isoforms in T cells (46, 47). Ikaros is
part of the Ikaros family, which includes Helios (Ikzf2), Aiolos (Ikzf3), Eos (Ikzf4), and Pegasus
(Ikzf5) (48). Ikaros expression is found in all hematopoietic cells, lymphoid lineages and some
myeloid cell subsets (49). Ikaros is implicated as a lymphocyte-specific lineage factor as mice that
are homzygous for the deletion of exon 3-4 (Dominant Negative) (50) or in exon 7 (Ikaros Null
system) (51) in both alleles fail to develop T, B, and NK cells and lack peripheral lymph nodes.
Additionally, Ikaros acts as a tumor suppressor gene as T cells that express the truncated
isoforms or engineered to be heterozygous for the exon 3-4 deletion (DN+/-) give rise to
lymphomas and leukemias (52, 53). Loss of complete Ikaros expression can bias cells towards a
transformed state (54). Similarly, reduced Ikaros or Ikaros exon deletions have been
characterized in human malignancies such as acute lymphoblastic leukemia (ALL) (55), acute
myeloid leukemia (AML) (56) and chronic myelogenous leukemia (CML) (54). Thus, Ikaros is a
key factor for T cell lineage regulation.
Ikaros acts through the formation of higher order chromatin binding complexes. DNAbinding to the GGGAA consensus binding site binding site (50) (46) (57) is achieved through
binding of at least 3 zinc fingers, especially by the exon 3-4 zinc fingers (50). Mice heterozygous
for this deletion results in enhanced ability of the truncated Ikaros isoforms to inhibit Ikaros and
the other family members (50, 52) and develop leukemias and lymphomas (52) (Fig 1A and B).
Ikaros forms cluster of dimers that associate with HDAC-containing Nucleosome Deacetylase
Complexes (NURDs) and repress chromatin through associating with Sin3a (58), Mi-2B (59) or in
an HDAC-independent manner with CtBP (60). Conversely, Ikaros can also act as an activator of
gene expression, through association with the SWI/SNF complex (61). Ikaros forms toroid

6

structures that localizes with the pericentromeric heterochromatin (53), an area associated with
gene silencing and resulting in Ikaros being mainly identified as a transcriptional repressor.
Another area of active research is on upstream regulators of Ikaros’ activity, as Ikaros
regulates many different target genes (Fig. 2) and thus requires accurate precision to be inhibited
or activated. Phosphorylation of Ikaros is one regulatory mechanism, as Casein Kinase II activity
on Ikaros results in its decreased binding activity (62) and can result in increased expression of
cell cycle genes such as c-Myc (63) and promote the G1-S transition phase (64). Other kinases
such as spleen tyrosine kinase (SYK) and Bruton’s tyrosine kinase (BTK) have also been
demonstrated to phosphorylate Ikaros in a similar fashion (65, 66). Hyper-phosphorylated Ikaros
is targeted for degradation (67) and complete loss of this tumor suppressor gene can bias
towards the development of leukemia and lymphomas (64, 67). Phosphorylation activity is
opposed by the activity of protein phosphatase 1 (PP1), that promotes Ikaros’ DNA binding
activity (67), recruitment to pericentromeric heterochromatin (62) and resist leukemic
transformation. Ikaros’ chromatin remodeling activity at the DNA levels is also regulated, as
SUMOlyation at K58 and K240 residues diminishes Ikaros repressive function through inhibiting
its ability to interact with HDACs (68). Thus, a combination of phosphorylation and SUMOlyation
activity help to regulate Ikaros activity, although the direct associations with T cell function and
proliferation remain to be worked out.

Ikaros in lymphocyte development
In the context of HSCs, Ikaros is expressed in early hematopoietic development and
observed in fetal thymus, liver and spleen (46, 69). In the adult, Ikaros expression is limited to the
lymphoid organs and blood leukocytes (57). Deficiencies in Ikaros during these developmental
stages can influence cell type expression. Mice that express a dominant negative form of Ikaros
typically have increases in GMPs (50) and MEPs (70) along with severe anemia, resulting from
decreases in erythroid precursors (50). Thus, alterations in Ikaros activity can impact
hematopoeisis.
With developing thymocytes, Ikaros activity is instrumental in regulating the development of
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a productive TCR, through regulation of RAG1 (70) and Tdt (71) genes, which assist in VDJ
recombination of TCR related genes. Similarly, Ikaros also regulates productive pre-BCR
formation through genetic control of the IgII1 locus (72) (73) in developing B cells. Ikaros is highly
expressed in thymocytes (69) and restricts thymocyte transitions through enforcing appropriate
pre-TCR signals in order to proceed (74). Following productive pre-TCR generation, Ikaros also
regulates the CD4+CD8+ double positive to single positive CD4+ or CD8+ thymocyte transition
as it has been linked to regulating both CD4 (75) and CD8 co-receptor expression (76, 77). In the
Ikaros DN system, there is an increase in CD4+ expressing thymocytes (75, 78) and both DP and
DN thymocytes give rise to transformed cells (52), indicating that Ikaros plays a role in the
thymocyte to naive T cell transition.

Ikaros in mature lymphocytes
Mature lymphocytes are split into B and T cells and form the humoral and cell mediated
immunity branches (CMI) of adaptive immunity. The humoral immune response involves the
activation of B cells, which secrete antibodies that are important for neutralization and antibody
dependent cell cytoxicity (ADCC) mechanisms to clear pathogens. The activation of B cells is
dependent on the CD4+ T cell arm of the CMI branch, as CD4+ T cells produce key cytokines
such as IL-4(79) to promote B cells immune responses. Ikaros has been implicated in the
regulation of different B cell targets such as transcription factors, cell cycle factors and chromatin
modifying agents(73). Aiolos also plays a role in B cell function as Aiolos-/- mice have increased
immature B cells, increase in autoantibody production, and development of B cell lymphomas
(80). Thus, Ikaros and its family member Aiolos play a role in regulating B cell development and
activation.
With mature T lymphocytes, Ikaros is known to have an extensive role in CD4+ T cells. First,
Ikaros plays a key role in CD4+ T cell anergy. This state of T cell unresponsiveness occurs when
self-reactive CD4+ T cells escape negative deletion mechanisms in the thymus and circulate into
the periphery. To prevent aberrant activation of autoreactive CD4+ T cells, naive CD4+ T cells
requires both TCR and CD28 co-stimulation. In the absence of CD28 co-stimulation, specifically
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by non-activated APCs in non-inflamed environments, these self-reactive CD4+ T cells fail to
become activated and re-engagement with TCR and CD28 signals in the periphery results in their
inability to be activated or produce IL-2(13). This anergic state is correlated with increasing levels
of Ikaros(14) and Ikaros is responsible for the increased de-acetylation of the IL-2 locus in
anergized CD4+ T cells (81). The direct regulation of the IL-2 locus by Ikaros in CD4+ T cells(19,
81) can also reverse this state of anergy, as in vitro anergized Ikaros-deficient CD4+ T cells
produce more IL-2 and avoid anergy (19). Additionally, IL-2 signaling can reduce Ikaros levels in
a T cell (82) and it is plausible that Ikaros and IL-2 act in a negative feedback loop. Thus, Ikaros
has an appreciable role for regulating CD4+ T cell responses to self-antigen through direct
regulation of the IL-2 locus. This regulation of IL-2 by Ikaros is also being extended to the other
Ikaros family members, such as Helios in Tregs(83) and Aiolos in Th17 CD4+ T cells(84).
In the context of CD4+ T cell differentiation, Ikaros represses Th1 differentiation under Th2polarizing conditions through the regulation of the T-box transcription factor T-Bet(85) and IFN-γ
gene expression(86). Under Th2-polarizing conditions, Ikaros-deficient CD4+ T cells up-regulate
T-Bet and produce more IFN-γ than wild-type polarized Th2 cells(86), indicating that Ikaros
regulates the plasticity of the Th1 and Th2 lineages. Additionally, Th2-polarized Ikaros-deficient
cells also demonstrate less repressive chromatin marks at the IFN-γ locus than wild-type Th2polarized cells, indicating that Ikaros has an epigenetic role on this locus. This regulation of IFNγ, helps to ensure appropriate immune responses as Ikaros-deficient Th2 polarized CD4+ T cells
respond to an in vivo Th2 polarizing stimulus in a Th1-responsive manner through aberrant
production of IFN-γ (86). In summary, Ikaros plays a critical role in both regulating CD4+ T cell
activation in response to appropriate stimulation and their differentiation.

Thesis Focus
As Ikaros has been characterized to restrict autocrine IL-2 production in CD4+ T cells via
transcriptional repression(19, 81) and regulates CD4+ T cell differentiation(86), I hypothesize that
Ikaros restricts autocrine IL-2 production in naive CD8+ T cells as means to regulate naïve CD8+
T cell differentiation. Thus, I have sought to determine how Ikaros influences naive CD8+ T cell
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differentiation through regulation of autocrine IL-2 production. In Chapter 2, I examine how Ikaros’
regulation of autocrine IL-2 production in naive CD8+ T cells influences their differentiation into
effector CTLs.
However, Ikaros activity is not restricted to just IL-2 regulation in CD8+ T cells and has been
linked to multiple genes (Fig. 2), and influences effector factors such as IFN-γ (86) and Granzyme
B (87, 88) in T cells. Thus, I have sought to also examine how Ikaros influences the effector
program, and in Chapter 3 I examine how CTLs with reduced Ikaros expression can improve the
efficacy of chimeric antigen receptor (CAR) engineered T cells. Finally, in the concluding chapter I
examine some preliminary data that indicates a role for Ikaros in memory CD8+ T cells. Overall,
Ikaros plays an important role in regulating the naive, effector and memory states of CD8+ T cell
biology.
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Figure	
  1:	
  The	
  8	
  known	
  isoforms	
  of	
  Ikaros	
  and	
  mouse	
  models	
  
	
  
Ikaros has 7 exons, with 4 N-terminal DNA binding C2H2 zinc fingers and 2 C-terminal
dimerization zinc fingers (Yellow). Ik1 and Ik2 isoforms are the predominant isoforms in T cells
(46, 57, 69). Deletion of Exon 3-4 regions results in the loss of DNA-binding activity and the
resulting truncated protein can act to inhibit full length Ikaros and the other family members via
the remaining dimerization domains. This results in a dominant negative activity in mice that are
heterozygous (52) for this deletion. Deletion in Exon 7 results in a non-productive transcript and
mice heterozygous for this deletion has 50% reduction in Ikaros (53), while homozygous mice
lack T, B, NK cells (51)
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Figure	
  2:	
  Ikaros	
  can	
  act	
  in	
  a	
  repressive	
  or	
  positive	
  action	
  on	
  gene	
  targets.	
  
	
  
Through the formation of higher order chromatin remodeling complexes and associations with
NURD and Mi-2B, Sin3a, CtB or SWI/SNF complexes, Ikaros can regulate the gene targets listed
in a positive or negative fashion.
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Figures modified from the submitted manuscript to Journal of Immunology, by O’Brien S et al.,
and titled “Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2
production”
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Abstract
Naive CD4+ T cells require signals from the TCR and CD28 to produce IL-2, expand, and
differentiate. However, these same signals are not sufficient to induce autocrine IL-2 production
by naïve CD8+ T cells, which require cytokines provided by other cell types to drive their
differentiation. The basis for failed autocrine IL-2 production by activated CD8+ cells is unclear.
We find that Ikaros, a transcriptional repressor that silences IL-2 in anergic CD4+ T cells, also
restricts autocrine IL-2 production by CD8+ T cells. Using a reductionist in vitro system, we find
that CD8+ T cell activation in the absence of exogenous cytokines and CD4 help leads to marked
induction of Ikaros, a known repressor of the Il2 gene. Naïve murine CD8 T cells haploinsufficient for Ikzf1 failed to upregulate Ikaros, produced autocrine IL-2, and differentiated into
IFN-γ-producing CTL in response to TCR/CD28 stimulation alone, and IL-2 was necessary for
this gain of effector function. Furthermore, Ikzf1-haploinsufficient CD8+ T cells were able to help
neighboring, non-IL-2-producing cells to differentiate into IFN-γ-producing effectors. Therefore, by
repressing autocrine IL-2 production, Ikaros ensures that naïve CD8+ T cells remain dependent
upon licensing by antigen presenting cells and CD4+ T cells, and may therefore act as a cellintrinsic safeguard against inappropriate CTL immunopathology, especially as inappropriate CTL
activation has been linked to autoimmune disease such as type I diabetes, vitiligo, and multiple
sclerosis.
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INTRODUCTION
Naive T cell differentiation is a tightly regulated process, as aberrant activation can lead to
immunopathology and disease. Naïve CD4+ and CD8+ T cells differ in their requirements for
differentiation, as the latter have higher cytotoxicity potential. Naïve CD4+ T cells require TCR
recognition of a cognate peptide in a class II MHC molecule and a costimulatory signal from
CD28-B7 engagement. Upon receiving these two signals, CD4+ T cells can produce autocrine IL2 and differentiate(1). In contrast, costimulation of naïve CD8+ T cells through the TCR and CD28
does not result in efficient autocrine IL-2 production, and is not sufficient for differentiation into
cytolytic effectors. In addition to TCR and CD28, CD8+ T cells require pro-inflammatory cytokines
for their differentiation. For instance, IL-12, type I IFN and IL-21 have been characterized as key
inflammatory cytokines that drive naïve CD8+ T cells into full-fledged cytotoxic effectors (3).
Typically, these cytokines are derived from dendritic cells or CD4+ T cells to help promote the
appropriate effector immune response.
Another cytokine that strongly influences CD8+ T cell responses is IL-2. This cytokine has a
pro-survival role through up-regulation of the anti-apoptotic factor Bcl-2, but also can influence
CD8+ T cell differentiation through affecting the balance of effector versus memory generation.
IL-2 is required during the priming phase for effective T cell memory formation, as “unhelped”
CD8+ T cells fail to generate memory(20, 42, 44). However, high levels of IL-2 can promote
terminal effector CD8+ T cell generation at the expense of memory formation (33, 36, 40). Thus,
strict regulation of IL-2 production during initial phases of an immune response ensures
appropriate CD8+ T cell differentiation. Naïve CD8+ T cells are highly restricted in their
production of autocrine IL-2(2) and are largely dependent upon IL-2 from CD4+ helper T cells (10,
11, 23). However, in some systems helper T cells can license CD8 cells to produce their own IL-2
(24), which is required during initial priming in order to generate robust memory recall responses
(25).
Little is known about how autocrine IL-2 is restricted in naïve CD8+ T cells. Recently, it was
shown that Ikaros, a transcriptional repressor required for lymphocyte development, restricts
autocrine IL-2 production in mature CD4+ T cells (19, 81). We hypothesized that Ikaros may
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similarly regulate naïve CD8+ T cell differentiation through inhibition of autocrine IL-2 production.
In this study, we demonstrate that TCR stimulation leads to strong induction of Ikaros unless
exogenous cytokines are present, and that naïve CD8+ T cells with reduced Ikaros function are
able to differentiate into cytolytic effectors in the absence of signal 3 cytokines and CD4 help due
to a gain of autocrine IL-2 function. Thus, by restricting autocrine IL-2 production by CD8+ T cells,
Ikaros ensures that induction of an inflammatory and cytotoxic program only occurs in cells that
have been appropriately licensed by a third signal.
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MATERIALS AND METHODS
-/-

Mice, Antibodies, Cytokines - Wild-type CD45.2, CD45.1, RAG1 and OT-1 mice were purchase
from JAX. Ikzf1+/- mice were a kind gift of Dr. Katia Georgepolous, and were backcrossed on a
B6 background for greater than 12 generations. RAG1

-/-

-/-

OT-1 Ikzf1+/- mice were generated
-/-

through breeding Ikzf1+/- mice onto a RAG1 background to obtain RAG1 Ikzf1+/- mice. These
-/-

mice were then crossed with the RAG1 OT-1 mice to generate the triple cross. Once the triple
cross was generated, these mice were maintained by crossing with RAG1
mice.

-/-

or RAG1

-/-

Ikzf1+/-

Ikzf1+/- PMEL mice were generated by crossing Ikzf1+/- mice with PMEL mice. All

procedures were approved by The Children’s Hospital of Philadelphia Research Institute animal
use and care committee. Monoclonal antibodies against CD3 (2C11), CD28 (37.51), CD4
(GK1.4), MHCII (M/5114), FcR (2.4G2), and IL-2 (JES6-1A12) were purchased from BioXcell and
anti-B220 (RA3-6B2), and anti-CD44 (IM7) antibodies were purchased from Biolegend. Mouse IL2 and IL-12 were purchased from Peprotech and Roche.

Cell Sorting - Single cell suspensions from spleen and LN of polyclonal mice were enriched for
CD8+ T cells through use of depleting antibodies against CD4 (GK1.4), MHC II (M5/114), antiFcR (2.4G2), anti-B220 (RA3-6B2) antibodies and Qiagen magnetic goat anti-rat IgG beads
(#310107), and sorted for naïve CD8+ T cells (CD62L

hi

-/-

CD44-) on a MoFlo XDP (Beckman
-/-

Coulter). Naïve CD8+ T cells were at >95% purity. RAG1 OT-1 and RAG1 Ikzf1+/- OT-1 single
cell suspensions from spleen and LN were depleted of CD4+ T cells, monocytes, and MHC IIexpressing cells with Qiagen magnetic goat anti-rat IgG beads (#310107). Cells were stained with
cocktail of depleting anti-CD4 (GK1.4), MHCII (M/5114), anti-FcR (2.4G2), anti-B220, and antihi

CD44 (IM7). Naïve OT-1 (CD62L CD44-) cells were purified to >90% purity.

Flow cytometry and applications - Fluorochrome conjugated antibodies against anti-mouse IFN-γ
(XMG1), anti-mouse CD25 (PC61), anti-mouse IL-2 (JES6-1A12), anti-mouse CD8 (53-6.7), antimouse CD45.1 (A20), anti-mouse CD62L (MEL-14), anti-mouse CD44 (IM7), anti-mouse CD4
(GK1.5) were purchased from Biolegend. Fixable, Live/Dead Aqua stain (L34957) was purchased
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from Invitrogen. Fluorochrome antibody to anti-mouse Granzyme B (NGZB), and anti-mouse
Eomes (Danmag11) were purchased from eBioscience. Fluorochrome anti-mouse T-Bet (4B10)
was purchased from BD Biosciences. CFSE was purchased from Invitrogen and 7-AAD was
ordered from Sigma-Aldrich. Negative gating was based on a ‘fluorescence-minus-one’ (FMO)
strategy. For intracellular cytokine staining, cells were treated with Golgi Stop (BD Biosciences,
0.66ug/ml) for 4-6 hours. Following harvesting, cells were fixed with 1% PFA for 30 minutes,
spun down and washed once with FACS buffer. Cells were then washed with BD Perm Wash (BD
Biosciences) 2 times and then stained with cytokine antibodies for 45 minutes at room
temperature. Cells were washed 2 times in BD Perm Wash, and then re-suspended in FACS
Buffer. For transcription factor staining, intracellular staining was achieved with the eBioscience
FoxP3 kit and standard protocols were followed.

Cell Culture - Naïve sorted CD8+ T cells were stimulated in 96-well or 24-well plates, which were
coated with anti-CD3/CD28 antibodies in PBS. All T cell cultures were maintained in RPMI
supplemented with 10% FBS, L-glutamine, Penicillin/Streptomycin, and 2-β Mercaptoethanol, and
maintained in 37C incubator. EL4 and EL4.OVA cells lines were maintained in DMEM,
supplemented with 10% FBS, L-glutamine, Penicillin/Streptomycin and 2-β Mercaptoethanol.
EL4.OVA cells were maintained in 400ug/ml G418 (Invitrogen).

Immunoblot analysis - Immunoblotting was performed for determining the Ikaros isoform
6

expression. For immunoblot, 0.5x10 cells were lysed with Laemmli buffer, boiled, and subjected
to SDS-PAGE using Criterion 10% precast Tris-HCl gels (Bio-Rad). Electrophoresed proteins
were transferred to nitrocellulose membrane using a Trans-Blot system (Bio-Rad). The
membrane was washed 3X with 0.1% Tween-20 in 1X PBS, and stained with a C-terminus
reactive goat anti-mouse antibody to Ikaros (SC-9861, Santa Cruz). Blots were washed and
incubated with secondary HRP-conjugated anti-goat antibody (1:10,000) for 1 hour at room
temperature. Membranes were then washed and developed using Super Signal West Pico
Chemiluminescent Substrate (Thermo Scientific). The image was developed on a Kodak X-ray
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film. Membranes were then stripped with Restore Plus Western Stripping Buffer (Thermo
Scientific) for 10 minutes, washed 3X, blocked, and stained with anti-goat antibody to β-actin
staining (Santa Cruz) to normalize loading.

Immunohistochemistry – 50-250 thousand cells were centrifuged onto glass slides and fixed for
20 minutes in 10% neutral buffered formalin. Immunohistochemical stains were performed on a
Bond III system (Leica Microsystems, Bannockburn, Ill) with pH6 epitope retrieval solution
(Leica), a HRP-conjugated anti-Ikaros primary antibody (ab26083, Abcam, Cambridge, MA)
diluted 1:1000 in IHC diluent (Leica), and with nuclear counter stain hematoxylin, following
manufacturer's protocol (standard protocol F, Leica) but eliminating steps to deparaffinize slides.
Stained slides were analyzed on a Leica DM 2500 microscope with a 40x HCX PL Fluotar
objective (∞/0.17/D). Images were captured using Leica application suite version 2.8.1 (build
1554, 2003-2007).

Cytotoxicity assays – Naïve purified OT-1 CD8+ T cells from Ikzf1+/+ or Ikzf1+/- mice were
stimulated with plate bound anti-CD3/CD28 (1.0ug/ml) for 48 hours and in presence or absence
of IL-2 (10ng/ml). Cells were then harvested, counted and re-suspended at 0.5e6 cells/ml in
complete RPMI and rested overnight at 37C. After overnight rest, effectors were mixed at 10:1
ratio with CFSE-labeled EL4 or EL4.OVA cells and incubated for 3 hours, 37C. After 3-hour
incubation period, cells were harvested, washed in FACS buffer, stained for CD8 expression and
live/dead viability was assessed after addition of 7-AAD (5ug/ml). Cells were analyzed by flow
cytometry and a standard number of flow cytometric beads were collected to standardize the
assay. CFSE+ tumor cells were gated on, and 7-AAD gating was measured against EL4 cells not
mixed with T cells. Percent killing by CD8+ T cells was calculated by the following fashion. %
Cytotoxicity of CD8+ T cells= (number of 7-AAD- cell counts/ total cell counts) *100. These
numbers were then normalized to the EL4 cell fraction that had no T cells added. Cytotoxicity =
(% Cytotoxicity of CD8+ T cells - % Cytotoxicity of Control Tumor cells without CD8+ T cells/
%Maximum cytolysis-%minimum cytolysis).
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In vivo tumor assay: Naïve purified wild-type and Ikzf1+/- PMEL CD8+ T cells were stimulated for
3 days with plate bound anti-CD3/CD28 (1.0ug/ml) for 3 days and in the presence or absence of
IL-12 (20ng/ml) or IL-12+IL-2 (10U/ml). After activation, cells were harvested and 1e6 cells were
transferred into B6 mice. After 24 hours, mice were challenged with 1e5 B16 melanoma
subcutaneously and tumor growth was followed. Tumors were measured with a ruler and tumor
volume was calculated as (LxW^2)/2 .
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RESULTS
IL-2 opposes Ikaros induction and promotes CD8+ T cell differentiation
To study the differentiation of naïve CD8+ T cells into effectors in a reductionist system, we
utilized agonistic anti-CD3 and anti-CD28 antibodies in an in vitro culture system devoid of other
cell types or exogenous cytokines. To control for previous antigen exposure, we used polyclonal
lo

hi

CD44 CD62L CD8+ T cells enriched by flow sorting, or monoclonal CD8+ T cells developed in
RAG1-/- OT-1 mice. Naïve, CD8+ T cells express the Ik1 and Ik2 DNA binding isoforms of Ikaros,
with no evidence for expression of the smaller isoforms that lack the DNA binding domain (Fig.
3A). Ikaros exhibited a punctate nuclear pattern by immunohistochemical staining (Fig. 3B),
consistent with previous studies (53). When costimulated through the TCR and CD28 in the
absence of exogenous cytokines, naïve cells showed marked upregulation of Ik1 and Ik2 (Fig. 3A
and B) and failed to differentiate into IFN-γ producing effector cells (Fig. 3D). The addition of
exogenous IL-2 reversed the accumulation of Ik1 and Ik2 proteins (Fig. 3A and C), and promoted
differentiation of naïve CD8+ T cells into IFN-γ producing effectors (Fig. 3D). These results
suggest that Ikaros, a known repressor of CD4+ T cell differentiation (19, 86) may also be
involved in cytokine-regulated CD8+ T cell differentiation.

Ikaros restricts CD8+ T cell differentiation in the absence of signal 3 cytokines
To determine whether Ikaros imposes a direct barrier to CD8+ T cell differentiation, we
utilized mice that carry one null and one wild-type allele of Ikzf1, the gene encoding Ikaros. This
model offers significant advantages over nullizygous mice, which do not develop an intact
lymphoid immune system (51), and over mice expressing a dominant-negative mutant of Ikaros
(50), which develop fatal lymphomas early in life (52, 53)in that Ikzf1+/- mice show normal
hematopoietic development and do not develop tumors (53). Naïve, quiescent CD8+ T cells with
only one functional allele of Ikzf1 failed to upregulate Ik1 and Ik2 in response to TCR/CD28
stimulation (Fig 4A and B). This failure was not due to under-stimulation of the cells by our in vitro
priming system as the wild-type and Ikzf1+/- CD8+ T cells up-regulated CD69, CD25 and CD44
following TCR and CD28 stimulation (Supp. Fig. 1). Consistent with our hypothesis that Ikaros

22

negatively regulates CD8 differentiation, Ikzf1+/- CD8+ T cells were able to differentiate in
response to TCR/CD28 costimulation alone (Fig. 4C), giving rise to frequencies of IFN-γ
producers comparable to that observed in wild-type cultures given exogenous IL-2 (Fig 4C). The
addition of exogenous IL-2 blunted the induction of Ikaros in wild-type cells (Fig. 4A and B), but
led to nearly complete loss of Ikaros in the Ikzf1+/- cells (Fig. 4A and B). Expression of the high
affinity IL-2 receptor by activated T cells is amplified and stabilized by IL-2, as IL-2-induced
STAT5 drives transcription of the cd25 gene in a feed-forward loop (26, 27). The high expression
of CD25 therefore suggested the presence of IL-2 in TCR/CD28 costimulated Ikzf1+/- cultures.
Consistent with this, neutralization of IL-2 completely blocked signal 3-independent CD25 and
IFN-γ expression (Fig. 4C) and prevented down-regulation of Ikaros by Ikzf1+/- cells (Fig. 4A)
indicating that the gain of function exhibited by these cells is entirely dependent upon IL-2.
We also assessed expression of the T-box transcription factors T-bet and Eomes (89, 90), as
IL-2 induces Eomes expression(36), and Ikaros has been shown to regulate T-bet during CD4+ T
cell differentiation (86). The strong TCR and CD28 signals in this system led to similar induction
of T-bet under all conditions (91) in both wild-type and Ikzf1+/- CD8+ T cells (Fig 4D), but
induction of Eomes by wild-type CD8+ T cells required exogenous IL-2. However, Ikzf1+/- CD8+
T cells were able to induce Eomes when stimulated without additional cytokines, to levels
comparable to that in wild-type cells primed in the presence of IL-2 (Fig 4D). These data indicate
that Ikaros also regulates the expression of Eomes, a key factor for CD8+ T cell effector
differentiation (89).

Ikaros influences CD8 differentiation via control of autocrine IL-2
The requirement for IL-2 in the differentiation of naïve Ikzf1+/- CD8+ T cells indicated that
loss of Ikaros function is accompanied by a gain of autocrine IL-2 production. To test this, we
measured IL-2 levels in the supernatants of wild-type and Ikzf1+/- cultures over 48 hours of
stimulation. Consistent with previous studies, wild-type naïve CD8 cells produced very little
autocrine IL-2 in response to TCR/CD28 costimulation (Fig. 5A). However, CD8+ T cells lacking a
single copy of Ikzf1 secreted significant levels of IL-2, and this was observed in both polyclonal
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cells and monoclonal OT-I cells (Fig. 5A). This gain of IL-2 production could also be observed at
the single-cell level immediately after TCR and CD28 stimulation (Fig. 5B).
To determine whether this enhanced IL-2 production is due to a reduced signaling threshold,
or is the result of an absolute gain of autocrine function by Ikzf1+/- cells, we varied the strength of
TCR or costimulatory signal received by the naïve cells in this system and measured T cell
activation and IL-2 production. Naïve, wild-type CD8+ T cells produced very little IL-2, and did so
only at 1.25ug/ml concentrations of αTCR antibody (Fig. 5C). Similarly, increasing the strength of
CD28 costimulation at a fixed, high concentration of αTCR antibody did not result in significant IL2 production by wild-type cells, but Ikzf1+/- cells showed a strong, dose-dependent increase in IL2 production under these conditions (Fig. 5C). Therefore, increasing TCR/CD28 signal strength
could not raise the wild-type level of autocrine IL-2 production to that of the Ikzf1+/- cells,
indicating that a loss of Ikaros function does not merely shift the T cell activation threshold, but
results in an absolute gain of autocrine IL-2 function by naïve CD8+ T cells.
Loss of Ikaros function leads to differentiation of a relatively high frequency of CD8 T cells in
this system, as measured by IFN-γ secretion at the single-cell level (Fig. 4C). While this was
clearly dependent upon IL-2 secretion by Ikzf1+/- CD8 cultures (Fig. 4C), our ICS data indicate
that this IL-2 is produced from relatively few cells at any one time (Fig 5B). To determine if Ikarosregulated autocrine IL-2 can also drive the differentiation of neighboring, non-IL-2 producers in a
paracrine manner, we utilized a mixed culture experiment. We mixed naïve-sorted, wild-type
CD45.1+ CD8+ T cells with naïve CD45.2+ Ikzf1+/- CD8+ T cells and activated them in vitro in
the presence or absence of IL-2. This would test if the increased autocrine IL-2 from mutant CD8
cells could act in a paracrine fashion on the wild-type cells to promote their differentiation. We
also used a suboptimal dose of anti-CD3/28 to increase dependency on cytokine signals for their
differentiation. As before, priming of Ikzf1+/- cells with anti-CD3/CD28 alone resulted in
differentiated CD25hi, IFN-γ producing cells, while wild-type cells failed to differentiate under
these conditions (Fig 6A). However, wild-type CD8+ T cells in the presence of Ikzf1+/- CD8+ T
cells became CD25hi, and a significant frequency was able to produce IFN-γ as measure by
intracellular staining (Fig 6A) and ELISA (Fig. 6B). To test if this was due to the increased
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autocrine IL-2 production from the CD8+ T cells with reduced Ikaros, cultures were also
stimulated in the presence of a neutralizing anti-IL-2 antibody. Blockade of IL-2 resulted in a
failure to differentiate into IFN-γ producing cells in these mixed cultures, indicating that the IL-2
from the Ikaros-mutant CD8+ T cells was necessary for both the autocrine and paracrine effects
on differentiation (Fig 6A). These data show that Ikaros controls not only the capacity of an
activated CD8+ T cell to produce autocrine IL-2, but also its ability to ‘help’ other activated CD8+
T cells to differentiate by providing paracrine IL-2 signals.

Ikaros indirectly controls CD8+ T cell cytotoxicity
To address how a loss of Ikaros function influences the secondary effector function of CD8+
T cells, we assessed Granzyme B expression and cytotoxic activity upon restimulation, functions
that are driven by IL-2 (33, 36, 92, 93). Wild-type CD8+ T cells primed through the TCR and
CD28 and re-challenged with PMA and ionomycin expressed low levels of Granzyme B (Fig. 7A),
and required the addition of exogenous IL-2 for high-level expression (Fig. 7A). However, Ikzf1+/effector cells were able to induce Granzyme B to high levels in the absence of exogenous
cytokines (Fig 7A), and this gain of Granzyme B expression was completely dependent upon IL-2
(Fig 7A). To assess cytolytic activity, wild-type and Ikzf1+/- OT-I cells were challenged in vitro
with EL4 thymoma targets engineered to express OVA (EL4.OVA). Wild-type OT-I cells primed
through the TCR and CD28 exhibited relatively poor cytotoxicity against EL4.OVA target cells as
measured by 7-AAD exclusion (Fig 7B) unless IL-2 was provided during the priming phase (Fig.
7B). However, consistent with their increased IL-2 and Granzyme B expression, TCR/CD28
primed Ikzf1+/- OT-I cells exhibited a cytotoxic capacity equal to that observed in wild-type cells
stimulated in the presence of IL-2 (Fig 7B). Together, our data indicate that the autocrine IL-2 that
is normally repressed by Ikaros is sufficient to drive naïve CD8+ T cells to differentiate into
cytotoxic, IFN-γ-producing effector cells, even in the absence of CD4+ T cell help and/or
exogenous cytokines like IL-2 or IL-12.
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Ikaros can regulate anti-tumor function in vivo
To test if the results of the in vitro cytotoxicity assay could translate in vivo, we utilized the
well-characterized B16 melanoma model. Transgenic PMEL-1 T cells recognize the tumor
antigen gp100(94), which is overexpressed by this poorly immunogenic tumor. Effective antitumor immunotherapy of established B16 tumors in mice usually requires the administration of
exogenous IL-2(95) or IL-12(96, 97) with adoptive transferred PMEL effectors and peptide
vaccination. Effective anti-tumor strategies also involves increased MHC I expression on B16
melanoma cells, and IFN-γ has been implicated as key cytokine for this system (98). Since our
Ikzf1+/- CD8+ T cells produce more IFN-γ upon stimulation with IL-12 (Fig 4C), and IL-12 also
improves IL-2 signaling (99, 100), we elected to prime our wild-type and Ikzf1+/- PMEL cells with
TCR, CD28 and in the presence or absence of IL-12 or IL-12+IL-2 signals. To test the fitness of
these effectors, the cultured effector CD8+ T cells were adoptively transferred into B6 mice and
24 hours later, injected with the highly aggressive and poorly immunogenic B16 melanoma. As
the transferred cells are the only tumor specific population in the mice, this tumor challenge
assesses the anti-tumor immunity of these in vitro cultured effectors and responsiveness in
absence of antigen specific CD4+ helper T cells.
Over the course of the experiment, the wild-type effectors primed in the presence of TCR and
CD28 alone promoted minor tumor delay by day 22 (Fig. 8A). Culturing these wild-type effectors
in the presence of IL-12 or IL-2+IL-12 promoted some tumor delay by day 19 in comparison to the
TCR and CD28 primed wild-type effectors, but by day 22 these stimulated effectors failed to
control tumor. Mice that received the TCR and CD28 primed Ikzf1+/- effectors demonstrated a
small, although not statistically significant, trend in tumor delay in comparison to the wild-type
effectors. Culturing these effectors in the presence of IL-12 did result in more pronounced tumor
delay in comparison to wild-type (Fig. 8B), indicating that these Ikzf1+/- effectors have increased
sensitivity to IL-12(101), produce more IFN-γ (Fig 4C), and promotes better effector function in
comparison to wild-type. More significant tumor delay was observed for the Ikzf1+/- effectors that
were stimulated with IL-2 and IL-12 (Fig. 8C). The increased tumor delay exhibited by the Ikzf1+/effectors in both the IL-12 and the IL-2/IL-12 stimulated groups demonstrates that the IL-12 alone
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group is similar to the IL-2+IL-12 group and enhancing IL-2 signaling. This increase in autocrine
IL-2 in combination with the inflammatory cytokine IL-12 results in Ikzf1+/- CD8+ effector
generation that has enhanced cytolytic function towards a poorly immunogenic tumor. Thus,
activating CD8+ T cells with reduced levels of Ikaros in the presence of an inflammatory
cytokines can promote an immune response to a self-antigen and Ikaros possibly influences
CD8+ T cell tolerance.
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DISCUSSION
In this chapter, we demonstrate a novel role for Ikaros in the regulation of naïve CD8+ T cell
differentiation through the control of autocrine IL-2. TCR signals in the absence of cytokines
results in accumulation of Ikaros at the protein level, imposing a barrier to IL-2 production and
effector differentiation. Extrinsic signals from IL-2 or IL-12 oppose the accumulation of Ikaros and
drive differentiation into IFN-γ producing CTL. Naïve CD8+ T cells with only one functional copy
of the Ikzf1 gene, which could not induce Ikaros to a significant degree, were able to differentiate
in the absence of CD4 help or cytokines. Neutralization of IL-2 blocked the capacity of both wildtype and Ikzf1+/- cells to differentiate. Thus, the repressive activity of Ikaros renders CD8+ T cells
dependent upon environmental cues such as IL-12 from activated dendritic cells, or IL-2 from
activated CD4+ T cells, to license their differentiation into effector CTL. Ikaros is also a potent
repressor of IL-2 and differentiation in CD4+ T cells (19, 81, 86), where a similar role for IL-2 in
the repression of Ikaros expression has been shown at the mRNA level (82). Thus, Ikaros
appears to integrate TCR, costimulatory and cytokine signals, where it mans a global checkpoint
for T cell differentiation.
IL-2 has important roles in CD8+ T cell effector differentiation and memory. IL-2 drives CD8
effector differentiation, in part by inducing the T-box transcription factor Eomes (36, 40), which
cooperates with its family member T-bet to transactivate IFN-γ, perforin, and Granzyme B gene
expression (89, 90). STAT5, a transcription factor activated by IL-2R signaling, has been shown
to promote accessibility of the Ifnγ promoter to binding by T-bet (102), and drives feed-forward
expression of the high affinity IL-2 receptor chain, CD25 (27). Indeed, expression of CD25 can
delineate effector from memory precursor cells. CD25 was shown to mark a terminally
differentiated population of highly cytolytic KLRG1+ effector cells during acute LCMV infection
(33), and high concentrations of exogenous IL-2 during CD8+ T cell activation in vitro results in
CTL with limited survival and homeostatic capacity (36). In contrast, low levels of IL-2 promote
the generation of effectors with reduced cytotoxicity and increased memory potential (36),
resembling the CD25lo memory precursor cells that arise during LCMV infection (33). While IL-2
is crucial for tuning effector CD8 differentiation, it is also required for CD8+ T cell memory. CD8+
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T cells primed in the absence of IL-2 signaling generate a blunted memory pool with poor recall
responses (42, 103, 104). Through the use of mixed bone marrow chimeras, it was demonstrated
that CD25-deficient memory CD8+ T cells were defective in IFN-γ and IL-2 production, and
exhibited poor cytotoxicity upon re-challenge with antigen. The use of IL-2/anti-IL-2 complexes,
mimicking IL-2 activity during primary immune responses also resulted in increased recall
responses (105) or converted IL-2Rα-/- CD8+ T cells into competent memory CD8+ T cells (42).
Adoptive transfer studies with naïve OT-I IL-2-/- into B6 mice and subsequent LM-OVA infection
also demonstrated that these cells fail to generate memory recall response (25). These studies all
demonstrate that naïve CD8+ T cells inability to respond to paracrine IL-2 or produce autocrine
IL-2 during a primary immune response will affect their requisite memory recall responses.
The main cellular source of IL-2 is CD4+ T cells, and along with CD40-mediated licensing of
dendritic cell maturation (22, 106, 107), IL-2 represents a major paracrine mechanism for CD4
help for CD8+ T cell responses (10, 11, 23). CD8+ T cells primed in the absence of CD4 help can
differentiate into effectors if other signal 3 cytokines are present, but are defective in
homeostasis, and exhibit markedly reduced proliferation, cytolytic capacity and cytokine
production when challenged with antigen during the memory phase (42, 44, 103). Consistent
with this, the il2 and ifnγ loci are epigenetically silenced in unhelped CD8+ T cells, at the level of
both DNA methylation and chromatin structure (20, 43). The phenotype of IL-2-deprived CD8+ T
cells is highly similar to that of memory CD8+ T cells generated in the absence of CD4 help,
suggesting a common molecular basis for the functional defect. Interestingly, it was recently
shown that CD4+ T cells can license CD8+ effector cells to produce their own IL-2 (24, 25),
implicating autocrine IL-2 as an important regulatory node in the development of effective CD8+ T
cell memory. Our current studies demonstrate a previously unappreciated role for the
transcriptional repressor Ikaros in the control of autocrine IL-2 production by CD8+ T cells.
Ikaros is a zinc finger DNA binding protein that interacts with the NURD, Sin3a and CtBP
transcriptional co-repressor complexes (58-60), and is a potent regulator of chromatin structure
and DNA methylation at its target genes (86). The repressive activity of Ikaros is required to
silence gene expression programs, ensuring that only those T cells that have received the
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appropriate instructive signals can develop and differentiate. For example, Ikaros binds to the Il2
promoter in naïve CD4+ T cells, keeping the chromatin in this region in a ‘closed’ conformation
unless signals from CD28 are received (19). Ikaros is also required to epigenetically silence the
genes encoding T-bet and IFN-γ in CD4+ T cells that fail to receive Th1-promoting signals from
IL-12 or IFN-γ, and cells with a loss of Ikaros function exhibit poly-lineage cytokine expression
patterns upon differentiation (86), and are resistant to anergy induction (19, 81). These studies
suggest that instructive signals from cytokines must oppose Ikaros-mediated repression at
lineage-specific effector genes. Indeed, IL-12 inhibits the binding of Ikaros to the endogenous
Tbx21 promoter in differentiating Th1 cells (86), and we show in this current study that IL-2 (Fig. 3
and 4) and IL-12 (Fig. 4A) can downregulate Ikaros in activated CD8+ T cells. These results also
provide an explanation for recent finding that CD8+ T cells transduced with a dominant-negative
Ikaros transgene are more responsive to IL-12 signaling (108).
These studies suggest a model in which Ikaros integrates signals from the TCR, CD28 and
the IL-2 receptor to regulate CD8+ T cell differentiation. We show that Ikaros is expressed in
naïve CD8+ T cells, and is highly induced upon TCR/CD28 costimulation. Our previous studies
indicate that targets such as Il2, Tbox genes, Gzmb, and Ifnγ would be subject to strong Ikaros
occupancy and repressive activity under these circumstances, and the chromatin at these genes
would be inaccessible to transcriptional activators induced during T cell activation. However, if a
naïve CD8+ T cell receives antigenic stimulation in the presence of paracrine IL-2 from a CD4+ T
cell, or IL-12 from the dendritic cell, our results show that Ikaros does not accumulate, and T-bet
and Eomes are induced instead. In the absence of the repressive activity of Ikaros, these factors
would then be free to bind to and transactivate the accessible Ifnγ, Gzmb and other loci to drive
effector differentiation.
Our studies also reinforce the importance of restricting autocrine IL-2 production by CD8+ T
cells. We show that naïve CD8+ T cells that do not express the appropriate level of Ikaros are not
only able to produce IL-2 and drive their own differentiation, they are able to help neighboring,
hi

non-IL-2 producing CD8 cells in a paracrine manner to differentiate into CD25 IFNγ+CTL. By
producing more autocrine IL-2 following TCR and CD28 stimulation, these Ikzf1+/- CTLs also
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have increased cytolytic function in vitro due to increased Granzyme B function. Their ability to
produce more IL-2, IFN-γ and Granzyme B, makes them ideal effectors for anti-tumor immunity.
Our in vivo tumor challenge model with a poorly immunogenic B16 melanoma demonstrated that
the Ikzf1+/- effectors that were primed with IL-12 or IL-2+IL-12 had enhanced anti-tumor
responsiveness to a self-antigen. While the wild-type cytokine primed effectors did not control the
tumor as well, this could be due to the use of the poorly immunogenic B16 as the more highly
immunogenic EL4.OVA system is typically utilized in the tumor prevention model(32).
Differences in CTL curative ability to EL4.OVA and B16.OVA established tumors following
vaccination with OVA has also been noted in the literature(109). Thus, we observe that the
increased sensitivity of Ikzf1+/- CD8+ T cells to IL-12(101) in combination with their increased
autocrine IL-2, results in robust CTL responses to a highly aggressive, poorly immunogenic
tumor.
This may have implications for autoimmunity as promoting Ikaros function could lead to novel
treatments for autoimmune disease or organ transplant rejection. Conversely, inhibition of Ikaros
activity could improve vaccination or anti-tumor immunity, where the lack of IL-2 derived from
CD4+ T cells in the tumor microenvironment poses a challenge for anti-tumor CD8+ T cells (110).
Importantly, we find that memory CD8+ T cells, which have been previously licensed and can
rapidly produce high levels of IFN-γ and IL-2 in response to antigenic stimulation, express lower
levels of Ikaros than naïve phenotype cells (Fig. 15), a finding predicted by our model of Ikaros
function. Together, our results show that Ikaros regulates CD8+ T cell differentiation by restricting
autocrine IL-2 production and enforcing dependence on paracrine signals from other cells.
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Figures

Figure	
  3:	
  Activation-‐	
  and	
  cytokine-‐dependent	
  Ikaros	
  expression	
  in	
  CD8+	
  T	
  cells.
	
  
Cells from RAG1-/- OT-1 mice were stimulated with plate bound anti-CD3 and anti-CD28
antibodies (1.0 μg/ml each) for 24 hours and in the presence (lane 3) or absence (lane 2) of IL-2
(10 ng/ml). Resting (lane 1) or stimulated (lanes 2 and 3) cells were washed in PBS,
immunoblotted (A, 0.33x106 cell equivalents), and probed with antisera against Ikaros (top
panels) or actin (bottom panels). The predominant Ik1 and Ik2 isoforms are indicated.
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Alternatively,

stimulated

cells

were

centrifuged

onto

glass

slides

and

subjected

to

immunohistochemical staining for Ikaros (B and C). Cells marked with an asterisk are highlighted
in individual panels at higher magnification. Anucleate, apoptotic cells show a low level of
background reactivity. Data are representative of 3 independent experiments. D. Naïve-enriched
RAG1-/- OT-I CD8+ T cells were stimulated with plate bound anti-CD3 and anti-CD28 (1.0, 0.5
μg/ml) in the presence (right panel) or absence (left panel) of IL-2 (10 ng/ml) for 48 hours, and
Golgi Stop was added for last 4 hours of stimulation. Cells were harvested, stained for CD8,
CD44 and IFN-γ, and subjected to flow cytometric analysis. Gates were set using a fluorescenceminus-one (FMO) approach, and plots depict IFN-γ expression by activated CD8+ (CD44hi) T
cells, with numbers indicating % IFN-γ+ cells. Data are representative of 3 independent
experiments.
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Figure	
  4:	
  CD8+	
  T	
  cells	
  hemizygous	
  for	
  the	
  Ikzf1	
  gene	
  express	
  less	
  Ikaros	
  and	
  show	
  reduced	
  
differentiation	
  requirements	
  compared	
  to	
  homozygous	
  cells.	
  	
  
Cells from RAG1-/- OT-1 Ikzf1+/+ (wild-type) or RAG1-/- OT-1 Ikzf1+/- mice were stimulated and
subjected to immunoblot (A) and immunohistochemical (B) analysis as in Fig. 3. Cells marked
with an asterisk are highlighted in individual panels at higher magnification. Data are
representative of 2 independent experiments. CD8+ T cells from Ikzf1+/+ or Ikzf1+/- OT-I mice
were sorted by naïve phenotype, stimulated with plate bound anti-CD3/CD28 (1.0, 0.5 μg/ml) plus
IL-2, IL-12 (10 ng/ml) or anti-IL-2 (10 μg/ml) for 48 hours, and analyzed for CD44, IFN-γ, and
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CD25 expression in (C) by flow cytometry as in Fig. 3D. Data are representative of 2 independent
experiments. Naïve sorted polyclonal CD8+ T cells (CD62Lhi CD44lo) from wild-type (black line)
and Ikzf1+/- (grey line) mice were stimulated in Fig. 2C although without the anti-IL-2 condition,
and assessed for CD44, T-Bet and Eomes expression by flow cytometry. Solid black histograms
depict FMO control. Data are representative of 2 independent experiments. For the plots in D, * is
p<0.05, ** is p<0.01, and *** is p<0.001 by Student’s T-test.
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Figure	
  5:Ikzf1+/-‐	
  CD8+	
  T	
  cells	
  produce	
  more	
  autocrine	
  IL-‐2	
  than	
  wild-‐type	
  CD8+	
  T	
  cells.	
  	
  
Naïve-enriched CD8+ T cells from Ikzf1+/+ or Ikzf1+/- B6 or OT-I mice were stimulated as in Fig.
3, and culture supernatants were assayed for IL-2 production by ELISA at the indicated time
points (A) or by intracellular staining at 6 (top panels) and 48 (bottom panels) hours post-
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stimulation (B). Plots in B are gated on activated cells. In C, naïve-enriched Ikzf1+/+ or Ikzf1+/OT-I CD8+ T cells were stimulated for 24 hours with either a fixed concentration of plate-bound
anti-CD28 and a titration of anti-CD3 (left panel), or a fixed concentration of anti-CD3 and a
titration of anti-CD28 (right panel). Data are representative of 2 independent experiments. * is
p<0.05, ** is p<0.01, and *** is p<0.001 by Student’s T-test.
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Figure	
  6:	
  IL-‐2	
  produced	
  by	
  Ikzf1+/-‐	
  CD8+	
  T	
  cells	
  can	
  act	
  in	
  a	
  paracrine	
  fashion	
  to	
  induce	
  
differentiation	
  of	
  wild-‐type	
  CD8+	
  T	
  cells.	
  	
  
Naïve-enriched CD8+ T cells from Ikzf1+/+ (CD45.1+) or Ikzf1+/- (CD45.2+) mice were stimulated
with plate bound anti-CD3 and anti-CD28 (1.0, 0.5μg/ml, respectively) in individual cultures or in
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co-cultures at a 1:1 ratio for 48 hours in the absence (B) or presence (C) of anti-IL-2 neutralizing
antibody (10μg/ml). Expression of CD25 and IFN-γ were assessed by flow cytometric analysis,
and numbers represent %IFN-γ+CD25+ cells. CD25 expression in Ikzf1+/+ (black) and Ikzf1+/(gray) cultures is also illustrated in histogram overlays (bottom panels in A-C). Supernatants from
these cultures were assessed for IL-2 and IFN-γ production by ELISA (D, E and F). Data are
representative of 3 independent experiments. * is p<0.05, ** is p<0.01, and *** is p<0.001 by
Student’s T-test.
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Figure	
  7:	
  Loss	
  of	
  Ikaros	
  function	
  leads	
  to	
  enhanced	
  cytolytic	
  capacity	
  by	
  CD8+	
  T	
  cells.	
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A. Naïve-enriched CD8+ T cells from Ikzf1+/+ (dark gray) or Ikzf1+/- (light gray) OT-I mice were
stimulated with plate-bound anti-CD3 and anti-CD28 (1.0 μg/ml) for 48 hours in the presence or
absence of IL-2 or anti-IL-2. PMA (30ng/ml) and ionomycin (1uM) were added for the last four
hours of culture. Expression of Granzyme B was assessed by flow cytometry. Data are
representative of two independent experiments. Filled black histograms - Granzyme B FMO
negative control. B. Ikzf1+/+ (dark gray) or Ikzf1+/- (light gray) OT-I cells were stimulated for 48
hours as in A, rested in medium overnight, then mixed at a 10:1 ratio with CFSE-labeled EL4 or
EL4.OVA targets for 3 hours. Cytotoxicity against the EL4 targets was assessed by flow
cytometry as described in the methods section. Data are representative of 2 independent
experiments. * is p<0.05, ** is p<0.01, and *** is p<0.001 by Student’s T-test.
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Figure	
  8.	
  Self-‐reactive	
  naive	
  CD8+	
  T	
  cells	
  with	
  reduced	
  Ikaros	
  are	
  more	
  sensitive	
  to	
  IL-‐2	
  and	
  IL-‐12	
  
signals	
  and	
  differentiate	
  into	
  cytolytic	
  effectors	
  with	
  enhanced	
  anti-‐tumor	
  immunity.	
  

Wild-type (Black) and Ikzf1+/- (Grey) PMEL naïve CD8+ T cells were cultured in the presence or
absence of IL-12 or IL-12+IL-12 along with TCR and CD28 stimulation and adoptively transferred
into B6 mice, and 24 hours later challenged with B16 melanoma. Each group had 3 mice and
each mouse was injected into two sites with 1e5 B16 melanoma. Tumors were evaluated up to 22
days before mice were sacrificed. * is p<0.05, ** is p<0.01, and *** is p<0.001 by 2-way ANOVA.
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Supplemental	
  Figure	
  1:	
  	
  CD69,	
  CD25	
  and	
  CD44	
  activation	
  are	
  similar	
  for	
  Wild-‐type	
  and	
  Ikzf1+/-‐	
  
naïve	
  CD8+	
  T	
  cells	
  following	
  initial	
  activation	
  with	
  TCR	
  and	
  CD28	
  
	
  
Naïve wild-type and Ikzf1+/- CD8+ T cells were stimulated for 12, 24 and 48 hours with plate
bound CD3/CD28 (1.0ug/ml) and then harvested for surface staining of CD69, CD25 and CD44.
Representative of two experiments.

43

CHAPTER	
  3	
  

Inhibition	
  of	
  Ikaros	
  activity	
  augments	
  
the	
  tumoricidal	
  capacity	
  of	
  CD8+	
  T	
  
cells	
  expressing	
  chimeric	
  antigen	
  
receptors2	
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Abstract
Adoptive transfer of T cells engineered with chimeric antigen receptors (CARs) has showed
significant promise in the treatment of cancer. These engineered T cells exhibit improved efficacy
in comparison to endogenous anti-tumor CTL due to improved tumor recognition and antigen
binding. This is achieved through the combination of an antibody extracellular single chain
fragment variable region (scFv) against a tumor antigen and an intracellular TCR signaling
domain. However, issues with CAR therapy remain, such as their ability to overcome the
immunosuppressive tumor microenvironment and negative T cell signaling regulators that prevent
aberrant T cell immune responses. Ikaros is one such negative regulator of T cell activation, as
Ikzf1+/- CD8+ T cells demonstrate enhanced in vitro cytolytic function due to their increased IL-2,
IFN-γ and Granzyme B production. We hypothesized that the enhanced effector function of
Ikzf1+/- CD8+ T cells could be utilized to improve the efficacy of CAR transduced T cells towards
both tumor cells and tumor stromal fibroblasts. We demonstrate that anti-mesothelin CAR CTLs
with reduced levels of Ikaros consistently lysed tumors and stromal fibroblasts, and mediated in
vivo tumor regression better than wild-type cells transduced with the same CAR. This increased
anti-tumor activity was accompanied by increased levels of IFN-γ, Granzyme B and TNF-α,
which characterize the activity of fully differentiated anti-tumor CTLs. Thus, inhibition of this
negative regulator of T cell activity has resulted in increased efficacy against tumor cells and
tumor stroma, and may provide a new approach for improving the efficacy of adoptively
transferred CAR CTLs to treat cancer.
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INTRODUCTION
In order to have an effective anti-tumor immune response, a CD8+ T cell has to overcome
many different obstacles. As many cancers are recognized as “self” through their expression of
tumor associated antigens (TAA) (111), most T cells fail to recognize the cancerous cell.
Additionally, through negative selection mechanisms in the thymus, most high avidity self-reactive
T cells are deleted in order to prevent autoimmunity (112), and any self-reactive T cells that do
escape typically have low avidity TCRs (113) (114). Thus, a pool of self-reactive CD8+ T cells
can exist in the periphery, but due to central tolerance mechanisms, these cells have poor
reactivity to the tumor.
One new approach to overcoming these hurdles is through the advent of chimeric antigen
receptors (CARs). This new technology fuses together an extracellular tumor antigen directed
antibody-derived single chain fragment variable (scFv) region with an transmembrane CD8α
hinge region and intracellular TCR and costimulatory signaling domains such as 4-1BB (115).
This construct bypasses the issues of low avidity TCRs, removes MHC Class I restriction and
allows for targeting of a wider array of cancer-associated antigens. CAR therapy has advanced
into the clinic and led to some recent clinic successes with B cell lymphomas (116) (117).
While advances in CAR therapy have brought improved anti-tumor efficacy, there are still
hurdles to overcome. CAR-engineered T cells need to overcome both intrinsic negative regulators
of T cell signaling such as diacylgylcerol kinases (118), and negative co-stimulatory proteins(such
as PD-1(119, 120), CTLA-4(121), TIM-3(120) and BTLA(122)) as both contribute to the
dampening of the T cell immune response. Tumor infiltrating lymphocytes typically express some
combination of these negative co-stimulatory receptors and engagement with their respective
ligand results in the inactivation of TILs. These TILs express less IL-2, TNF-α and IFN-γ(120),
and as a result are less efficient at tumor control(121). This decrease in cytokine production could
be linked to epigenetic changes at the cytokine gene locus, although presently there are few
reports demonstrating that TILs have increased repressive marks at cytokine genes(123).
However, TILs that are activated in the absence of CD4+ T cells in the tumor microenvironment
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(110), are also similar to “unhelped” effector cells that also produce less IFN-γ than helped
counterparts, due to expressing more repressive chromatin markers at the IFN-γ locus (20).
Thus, by targeting transcription factors that epigenetically modify the IL-2 and IFN-γ loci, it could
be possible to reverse the loss of cytokine gene expression in CAR-engineered tumor infiltrating
lymphocytes, bypass the function of negative regulators, and thus improve tumor immunotherapy.
One such negative regulator is Ikaros, which is a zinc finger DNA binding protein that
negatively regulates gene expression through the recruitment of chromatin remodeling
complexes, such as Sin3A(59), CtBP(60) and HDACs(58). Ikaros has been characterized as a
negative regulator of IL-2 production in both CD4+(19) and CD8+ T cells (Chapter 2). T cells that
express dominant negative isoforms of Ikaros (IkDN+/-)(52)have less repressive chromatin marks
on the IL-2 and IFN-γ loci(86) and produce more of these cytokines upon stimulation(19, 86).
Similarly, activated naive Ikzf1+/- CD8+ T cells produce more autocrine IL-2 and can differentiate
into effectors with enhanced cytolytic function in vitro due to increased IFN-γ and Granzyme B
production (Chapter 2). This enhanced cytolytic function in Ikzf1+/- CD8+ T cells makes Ikaros an
attractive target to inhibit for tumor immunotherapy. Thus, I hypothesized that introducing a CAR
construct into T cells with reduced Ikaros expression would improve their ability to differentiate
into CTLs with enhanced lytic function.
In this chapter, I demonstrate that the ability of CAR-transduced T cells to respond to
antigens expressed by tumors and the tumor stroma is enhanced in T cells with reduced Ikaros
(IkDN+/- and Ikzf1+/-), and that these CAR-engineered Ikaros-deficient T cells have improved
CTL function in vitro and in vivo. Thus, targeted inhibition of this negative transcription regulator,
Ikaros, in CD8+ T cells may provide a new avenue for improving the efficacy of CAR therapy.
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MATERIALS AND METHODS
Mice, Antibodies - Wild-type CD45.2, were purchased from JAX. Ikaros DN+/- and Ikzf1+/- mice
were a kind gift of Dr. Katia Georgepolous, and were backcrossed on a B6 background for
greater than 12 generations.

All procedures were approved by The Children’s Hospital of

Philadelphia Research Institute animal use and care committee.

T cell transductions- cDNAs for a mesothelin CAR or a FAP CAR, which consists of an antibodybinding region for human mesothelin or mouse FAP fused to a CD8 transmembrane domain,
CD3z, and 4-1BB costimulatory domains, were subcloned into a MIGR retrovirus. This vector
expresses GFP. Transfections were conducted with Lipofectamine 2000 (Invitrogen) and
infectious particles were collected from transfected 293T with the MIGR retrovirus and helper
plasmids. T cells were purified from single cell suspensions of wild-type, Ikzf1+/- and IkDN
spleens as suggested by the manufacturer (Miltenyi Biotec). Cells were stimulated with plate
bound anti-CD3 (1 mg/ml) and anti-CD28 (2 mg/ml) in 100U/ml IL-2 at 4e6 cells/well in 24 well
plates. After 48 hours, 1e6 cells/well were mixed with retrovirus (1ml crude viral supernatant) in
24 well plate coated with Retronectin (50 mg/mL; Clontech) and centrifuged without braking at
room temperature for 30 minutes at 1,200 g. After overnight incubation, cells were expanded with
100 U/mL of IL-2 for 7 days. After 7 days, transduction efficiency was checked for %GFP+
expression by flow cytometry on a Beckman Coulter CyanADP.

Bead Preparation- BSA or human mesothelin (1 or 5ug, RayBiotech, #230-00043) were
chemically cross-linked to tosylactivated 4.5mm Dynabeads (Invitrogen #140-13) as previously
described(124)

In vitro Cytotoxicity and IFN-γ ELISA Assays- T cells were co-cultured with luciferase-expressing
mouse mesothelioma cell line AE17meso or the parent cell line, AE17, at different effector to
target ratios for 18 hours, in triplicate in 96 well round bottom plates. Cell lysis was determined by
lucerifase release as previously detailed(124). Supernatants were also characterized for IFN-γ by
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ELISA kit (Biolegend). This assay was also conducted with NIH 3T3 cell lines that were
engineered to express mouse FAP.

In vivo tumor models- For the Winn’s Assay, T cells were mixed at the effector:target ratio of 0.5:1
with the AE17meso or AE17 and injected into the right flank of B6 mice. Tumor volume was
assessed by calipers and over a 16-day period until mice were euthanized. For established tumor
model, B6 matched mice were injected with 2e6 AE17meso cells. 7 days later, mice were injected
after tumors grew to 100mm3. Mice received via tail vein injections 10e6 CAR-engineered wildtype or Ikzf1+/- T cells. Tumors were measured by calipers and assessed for additional 10 days.
Tumor volume was calculated by the formula 0.52(a^2)(b), with a representing the minor axis and
b representing the major axis.

Flow cytometric assays- Fluorochrome conjugated antibodies against anti-mouse IFN-γ (XMG1),
anti-mouse CD25 (PC61), anti-mouse IL-2 (JES6-1A12), anti-mouse CD8 (53-6.7), anti-mouse
CD44 (IM7), and anti-mouse CD4 (GK1.5) were purchased from Biolegend. Fixable, Live/Dead
Aqua stain (L34957) was purchased from Invitrogen. Fluorochrome antibody to anti-mouse
Granzyme B (NGZB) was purchased from eBioscience. Fluorochrome antibodies to anti-mouse
TNF-α (MP6-XT22) and anti-mouse CD69 (H1.2F3) were purchased from BD Biosciences. For
intracellular cytokine staining, cells were treated with Golgi Stop (BD Biosciences, 0.66ug/ml) for
4-6 hours. Following harvesting, cells were fixed with 1% PFA for 30 minutes, spun down and
washed once with FACS buffer. Cells were then washed with BD Perm Wash (BD Biosciences) 2
times and then stained with cytokine antibodies for 45 minutes at room temperature. Cells were
washed 2 times in BD Perm Wash, and then re-suspended in FACS Buffer.
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RESULTS
To study how reduced Ikaros expression in a CAR-engineered T cell could enhance their
anti-tumor effect, we utilized the Ikzf1+/- mouse model. Ikzf1+/- T cells express approximately
50% less Ikaros protein than wild-type TCR and CD28 stimulated T cells (Chapter 2) (53) and
also develop an intact hematopoietic systems in comparison to nullizygous mice (51) and avoid
lymphoma development like the Ikaros dominant-negative system(52).
As Ikaros is a negative regulator of CD8+ T cell function (Chapter 2), we sought to adapt
them to our CAR transduction system to test if they could improve the efficacy of CAR therapy.
We initially tested them with an anti-human mesothelin CAR, which has a antibody derived
soluble chain Fragment variable (scFv) region to mesothelin, which is typically overexpressed in
human mesotheliomas, pancreatic and ovarian cancers(125). This extracellular domain is
coupled to a CD8α transmembrane domain and to intracellular 4-1BB and CD3ζ signaling
domains.
As CTLs produce IFN-γ and lytic mediators such as Granzyme B and TNF-α, we assessed
for any differences in production of these factors by the wild-type and Ikzf1+/- CD8+ T cells.
Additionally, we also assessed their ability to respond to low and high amounts of antigen
availability by mixing the T cells with anti-mesothelin coated beads with 1 or 5ug of mesothelin.
As a positive control, cells were also stimulated with PMA/I. With the wild-type T cells, they
expressed similar frequencies of IFN-γ regardless of the amount of mesothelin antigen present
(Fig 9A). The wild-type cells also expressed similar levels of Granzyme B and TNF-α regardless
of the amount of antigen they were presented with (Fig 9A). In contrast, the Ikzf1+/- T cells
produced more IFN-γ, Granzyme B and TNF-α at low dose of mesothelin coated beads in
comparison to the wild-type T cells. At the higher dose of mesothelin-coated beads, the Ikzf1+/continued to produce more of these factors in comparison to wild-type. Thus, the Ikzf1+/- T cells
produce more lytic mediators at low dose of antigen in comparison to wild-type T cells.
To test if the increased IFN-γ, Granzyme B and TNF-α of Ikzf1+/- T cells could contribute to
enhanced lysis, cells were mixed at different ratios with the parental cell line, AE17 or the
mesothelin expressing cell line, AE17meso. These cell lines also express luciferase, which was
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utilized as readout of cytolytic function. With the parental cell line, both the wild-type and Ikzf1+/T cells failed to produce IFN-γ or lyse cells in response to AE17 (Fig 10A and B). In the presence
of AE17meso, the level of IFN-γ production and lysis by the wild-type T cells declined as the
number of wild-type cells to target cells were titered down (Fig 10A and B). In contrast, at high
effector to target ratios the Ikzf1+/- T cells produced more IFN-γ and had increased lysis than
wild-type and continued to do so at even very low effector to target ratios (Fig 10A and B). Thus,
the observed increases in IFN-γ, Granzyme B and TNF-α contributed to increased cytolytic
function in vitro by the Ikzf1+/- T cells.
To further demonstrate that reducing Ikaros levels in effector CTLs could result in enhanced
effector function, we also utilized the Ikaros DN+/- system. These mice are heterozygous for a
deletion in exon 3-4 of Ikaros, and result in truncated Ikaros isoforms that act in a dominant
negative fashion on Ikaros(52) and reduce Ikaros at levels greater than the Ikzf1+/- T cells. In
utilizing the same in vitro cytotoxicity assay with anti-human mesothelin CAR engineered wildtype and Ikaros DN T cells, the Ikaros DN+/- T cells also demonstrated greater levels of IFN-γ
production and increased lysis in comparison to their wild-type counterparts (Fig 11A and B).
Thus, greater reductions of Ikaros activity continued to result in enhanced production of IFN-γ
and cytolytic function.
To verify that these in vitro results could be applied in vivo, we utilized two in vivo models. In
the Winn’s Assay, the wild-type T cells failed to provide much delay in AE17meso tumor growth
and the tumors grew appreciably (Fig 12A). In contrast, the Ikzf1+/- T cells were able to provide
more durable tumor delay. To further follow up on these results, these set of T cells were also
adoptively transferred into mice with established AE17meso tumor. Following T cell transfer, the
wild-type cells provide minimal tumor delay and tumor volume began to increase 10 days posttransfer (Fig 12B). In contrast, the adoptively transferred Ikzf1+/- T cells were more effective at
delaying tumor growth, as the tumor volume remained stable and did not increase appreciably as
with the wild-type cells post-transfer (Fig 12B). Thus, in two in vivo models of cancer, the Ikzf1+/transduced T cells displayed better anti-tumor immunity than their wild-type counterparts.
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The tumor microenvironment is composed of multiple cell types that produce pro-angiogenic
factors (126) and thus represent a logical target to inhibit tumor growth. One such cell type of
interest is tumor stromal fibroblasts, which express the fibroblast activation protein (FAP), and is
typically expressed in most tumors. Thus, we also decided to test if an anti-FAP CAR in Ikzf1+/- T
cells could have an additive anti-tumor effect, just as we demonstrated with the anti-mesothelin
CAR transduced T cells.
In in vitro assays with a FAP-expressing 3T3 cell line, the wild-type T cells produced minimal
levels of IFN-γ production (Fig 13A). Additionally the wild-type cells were only efficient at lysis
with high effector to target cell ratios (Fig 13B). In contrast, Ikaros deficiency resulted in these
transduced T cells producing more IFN-γ and increased cytolytic function even at lower effector
to target ratios (Fig 13A and B). Thus, reduced Ikaros in T cells expressing a FAP CAR results in
their enhanced effector function in vitro. To determine if targeting FAP-expressing cells in vivo
could result in diminished tumor growth by AE17meso tumors, mice with established AE17meso
were injected either with wild-type or Ikzf1+/- transduced anti-human FAP CAR T cells. Mice
receiving wild-type transduced cells provided minimal tumor delay and the AE17meso tumors
continued to grow. In contrast, the Ikzf1+/- transduced T cells were able to delay tumor growth
(Fig 13C), and demonstrate that targeting the tumor stroma could prevent their pro-angiogenic
properties that are necessary for tumor growth.
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DISCUSSION
CAR therapy represents a new therapeutic avenue in the field of cancer immunotherapy. It
represents a major step forward through improving the binding affinity of a T cell to a non-MHC I
restricted tumor antigen and also removing the requirement for co-stimulatory molecules through
utilizing intracelluar co-stimulatory signaling domains in the CAR construct. This study
demonstrates for the first time that targeting of a negative transcriptional regulator, Ikaros, in CAR
transduced T cells results in enhanced anti-tumor activity in vivo. Thus, Ikaros inhibition could
represent a new therapeutic target for CAR therapy.
Revitalizing TILs in the tumor microenvironment represents a major goal of cancer
immunotherapy and has been targeted in many different ways. As TILs up-regulate negative
ligands such as CTLA-4(127), PD-1(119, 120), TIM-3(120), or BTLA(122), these cells typically
develop a hypofunctional state and lose their ability to produce key effector cytokines and lytic
products. Strategies to restore TIL function have involved the use of antibodies to these inhibitors
or their respective ligands and have resulted in the restoration of effector function to this
population of cells. However, while blockade of these inhibitors results in better anti-tumor
immunity, there have also been instances in which these T cells cause autoimmunity (127-129).
Another approach to revitalize TILs has been through the targeting of intrinsic T cell signaling
regulators. Improved CAR efficacy has been demonstrated upon inhibition of diacylglycerol
kinases(124), as T cells lacking DGK-α/ζ activity no longer inhibit the Ras signaling pathway.
In this chapter, I report on a new approach to improving T-cell mediated immunotherapy,
through targeting of Ikaros, a transcriptional repressor involved in T cell differentiation. In CD4+ T
cells, Ikaros regulates the Th1 and Th2 differentiation pathway through tight regulation of T-Bet
expression in Th2 polarized cells. In Th2 polarized Ikaros-deficient CD4+ T cells, the cells take on
a Th1 phenotype through being able to produce IFN-γ and express the Th1-transcription factor TBet(86). Likewise in Ikzf1+/- naive CD8+ T cells, these cells only require TCR and CD28 costimulation as their increased autocrine IL-2 production promotes their ability to differentiate into
CD25hi, Eomes+, IFN-γ, Granzyme B+ effector cells (Chapter 2) with enhanced effector function.
Additionally, this negative repressor has been associated with the direct repression of IL-2 in T
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cells(19), and T cells with reduced Ikaros also exhibit more permissive chromatin marks at the
IFN-γ locus(86). Finally, Ikaros is an ideal candidate to target for restoration of T cell effector
function, as CD4+ T cells deficient in Ikaros are resistant to anergy (19) and CD8+ T cells no
longer require Signal 3 cytokines (3) for CD8+ T cell effector differentiation (Chapter 2). Thus, T
cells with reduced Ikaros expression are able to differentiate into T cells with enhanced effector
function and bypass the typical requirements for appropriate differentiation.
In the context of priming T cells in the tumor microenvironment, utilizing CD8+ T cells with
reduced Ikaros presents added advantages. The tumor microenvironment is devoid of
inflammatory cytokines to mediate CD8+ T cell differentiation and may not have appropriate
CD4+ T cell help present for CD8+ T cell differentiation, however Ikzf1+/- CD8+ T cells can
overcome these issues as they can be activated in the absence of these factors (Chapter 2). Due
to chronic antigen being present in the tumor microenvironment, the TILs upregulate negative costimulatory ligands and upon their engagement, results in decreased IL-2, TNF-α and IFN-γ, and
possibly due to increased repressive marks(123). By targeting Ikaros activity in CD8+ T cells, this
hyporesponsive state can possible be reversed as Ikaros deficient T-cells have permissive
chromatin at cytokine genes(86) and typically produce more cytokines(86)(Chapter 2). Thus, an
Ikzf1+/- TIL may thrive in the immunosuppressive microenvironment due to their enhanced
functionality.
As demonstrated in our in vitro systems, the Ikzf1+/- T cells can thrive with low levels of
antigen present and produce high amounts of IFN-γ, TNF-α and Granzyme B. This is an added
advantage in a tumor environment with low antigen availability, as the Ikzf1+/- T cells can
produce high amounts of lytic mediators. Additionally, the high amount of IFN-γ would be
expected to mediate additional anti-tumor activity, as IFN-γ has been denoted to up-regulate
Class I MHC expression on the tumor(130) and thus improving its immunogenicity, recruiting
macrophages to the tumor for phagocytic activity(131), anti-angiogenic activity(132) and driving
STAT1 mediated function of Th1 cells(133). The increase in the lytic mediators of TNF-α and
Granzyme B in our Ikzf1+/- CD8+ T cells results in increased killing of tumor targets in vitro and in

54

vivo, again demonstrating that a CD8+ T cell with reduced Ikaros in the tumor microenvironment
will have enhanced effector function (Chapter 2).
While CAR therapy has been initially developed to target antigens expressed on cancer cells,
such as CD19(116) and mesothelin (124, 134, 135), it is now expanding to include other cell
types that contribute to tumor growth. CARs are now being developed towards VEGFR-1(136),
and FAP-α (137). Our results with the anti-FAP CAR-engineered Ikzf1+/- T cells demonstrate that
targeting the tumor stroma is a viable option for controlling tumor growth. (137). Thus, inhibition of
a negative transcriptional regulator can improve the efficacy of both CAR-engineered T cells
directed toward tumor antigens and non-tumor antigens.
In targeting both tumor cells and the tumor stroma, CAR-engineered T cells on an Ikzf1+/background demonstrate enhanced anti-tumor effects in vitro and in vivo. As mesothelin is a selfantigen, and expressed in mesothelial cells that line the lung, heart, spleen, kidney and testis,
(138) it is plausible that anti-mesothelin CAR-T cells could have some off-target effects. While
our in vivo experiments have not demonstrated any toxicity, there have been reports of CARengineered T cells causing toxicity(139, 140). Thus, with our Ikzf1+/- CAR-engineered T cells
requiring little antigen in order to promote their activation (Fig. 9), we will need to determine if
Ikaros deficiency may promote any off target effects.
In conclusion, our report demonstrates that Ikaros could be a valid target for inhibition, as
means to improve the efficacy of CAR expressing TILs. Inhibiting Ikaros expression to 50% levels
as in the Ikzf1+/- T cells (53) or further reduced in the Ikaros DN+/- T cells demonstrates how
CTLs with reduced Ikaros have enhanced effector function. One could envision studies in which
CAR transduced T cells are treated with an inhibitor of Ikaros, to promote the differentiation of the
CD8+ T cell into a CTL with enhanced anti-tumor activity. This may help anti-tumor CD8+ T cells
to overcome the hurdles of the immunosuppressive tumor microenvironment.
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Figure	
  9:	
  Ikzf1+/-‐	
  T	
  cells	
  produce	
  more	
  IFN-‐γ,	
  TNF-‐α	
  and	
  Granzyme	
  B	
  in	
  comparison	
  to	
  wild-‐type	
  
stimulated	
  T	
  cells	
  with	
  low	
  or	
  high	
  dose	
  of	
  antigen-‐coated	
  mesothelin	
  beads.	
  
Wild-type and Ikzf1+/- CAR-engineered T cells were mixed with BSA, mesothelin (1ug, 5ug)
coated beads or PMA/I (30ng/ml, 1nM) for 6 hours and assessed by ICS. T cells were assessed
for IFN-γ (A), TNF-α (B) and Granzyme B (C) by ICS. * is p<0.05, ** is p<0.01, and *** is
p<0.001 by Student’s T-test.
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Figure	
  10:	
  Ikzf1+/-‐	
  T	
  cells	
  transduced	
  with	
  anti-‐human	
  mesothelin	
  CAR	
  produce	
  more	
  IFN-‐γ	
  and	
  
Granzyme	
  B,	
  and	
  have	
  increased	
  cytolytic	
  function	
  in	
  vitro	
  upon	
  challenge	
  with	
  antigen	
  
expressing	
  tumor	
  cell	
  line.	
  	
  
Wild-type and Ikzf1+/- transduced T cells with anti-human mesothelin CAR were challenged with
the luciferase-expressing tumor cell line AE17 or AE17meso at different effector to target rations
for 18 hours and supernatants were collected for IFN-γ ELISA (A). Release of luciferase was
used as a read-out for in vitro cytotoxicity (B). * is p<0.05, ** is p<0.01, and *** is p<0.001 by
Student’s T-test.

57

*
*

*
*

*

*

Figure	
  11:	
  Anti-‐mesothelin	
  CAR-‐engineered	
  Ikaros	
  DN+/-‐	
  T	
  cells	
  have	
  enhance	
  cytolytic	
  function	
  
in	
  vitro	
  and	
  produce	
  more	
  IFN-‐γ	
  than	
  wild-‐type	
  T	
  cells	
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Wild-type and IkDN+/- transduced T cells with anti-human mesothelin CAR were challenged with
the luciferase-expressing tumor cell line AE17 or AE17meso at different effector to target ratios
for 18 hours and supernatants were collected for IFN-γ ELISA (A). Release of luciferase was
used as a read-out for in vitro cytotoxicity (B). 5-10 mice per group were used. * is p<0.05, ** is
p<0.01, and *** is p<0.001 by Student’s T-Test.
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Figure	
  12:	
  Ikzf1+/-‐	
  T	
  cells	
  transduced	
  with	
  anti-‐human	
  mesothelin	
  CAR	
  have	
  enhanced	
  anti-‐
tumor	
  in	
  vivo	
  properties	
  in	
  comparison	
  to	
  wild-‐type	
  transduced	
  T	
  cells.	
  

In 12A, a Winn’s assay was performed by having wild-type (square) and Ikzf1+/- (diamond)
transduced T cells mixed with the mesothelin-expressing tumor cell line AE17 (AE17meso) at a
ratio of 0.5:1 (T cell: Target cell) and then subcutaneously injected into B6 mice. Tumor volume
was measured over a 16-day period. In 10B, B6 mice were injected with 2e6 AE17meso cells and
grew to 100mm3. 10 days post-injection, tumor bearing mice were separated into untreated
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(diamond) or received 10e6 wild-type (square) or Ikzf1+/- (triangle) transduced anti-human
mesothelin CAR T cells and tumor volume was measured following the injections. 5-10 mice per
group were utilized. * is p<0.05, ** is p<0.01, and *** is p<0.001 by Student’s T-test.
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Figure	
  13:	
  Ikzf1+/-‐	
  transduced	
  T	
  cells	
  with	
  anti-‐FAP	
  CAR	
  have	
  enhanced	
  IFN-‐γ	
  and	
  cytolytic	
  
functions	
  in	
  vitro	
  in	
  comparison	
  to	
  wild-‐type	
  transduced	
  cells	
  and	
  promote	
  tumor	
  delay	
  of	
  
AE17meso	
  implanted	
  tumors.	
  
As in Figure 8, wild-type and Ikzf1+/- transduced T cells were assessed for their ability to produce
IFN-γ and kill a 3T3 cell line expressing FAP by ELISA (A) and through a luciferase release assay
(B). In C, B6 mice were injected with 2e6 AE17meso cells and after tumors grew to be 100mm3,
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mice were either untreated (circle) or injected with 10e6 wild-type (square) or Ikzf1+/- transduced
anti-human FAP CAR T cells. Tumors volume was measured following initial tumor dose
inoculation and after T cell transfer. For tumor model, 5-10 mice were used per group. * is
p<0.05, ** is p<0.01, and *** is p<0.001 by Student’s T-test.
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In this chapter, I highlight some preliminary data that has interesting future implications
and reveals new roles for Ikaros in the context of CD8+ T cell biology. These preliminary data
outlines how naïve Ikzf1+/- CD8+ T cells can differentiate in vitro in response to TCR signals
alone. This result is similar to how memory CD8+ T cells become activated in the absence of
inflammatory signals and CD28 signals, and regulate Ikaros expression. Finally, I conclude with
implications for how targeted inhibition of Ikaros could bypass the requirement for CD4+ T cell
help and lead to the revitalization of TILs and exhausted CD8+ T cells.
Ikaros enforces the CD28 costimulatory requirement for naïve CD8+ T cell activation
As outlined in Chapter 2, naïve Ikzf1+/- can differentiate with TCR and CD28 signals in
the absence of inflammatory cytokines and CD4 help due to their increased autocrine IL-2. As IL2 signals can replace the CD28 costimulation requirement(141) and Ikaros enforces the CD28
costimulatory requirement for IL-2 activation in CD4+ T cells(19), I investigated if our naïve
Ikzf1+/- CD8+ T cells could differentiate in our in vitro priming system in the presence of TCR
signals alone or with anti-IL-2.
In using the same in vitro priming approach in Chapter 1, naive sorted polyclonal or OT-1
cells from wild-type and Ikzf1+/- mice were stimulated only in the presence of plate bound antiCD3. In the absence of CD28 signals and exogenous cytokines, the activated wild-type cells
failed to become IFN-γ producing CTLs (Fig. 14A and C). In contrast, the stimulated Ikzf1+/CD8+ T cells could differentiate into IFN-γ producing CTLs and this differentiation program was
again observed due to increased autocrine IL-2 production (Fig. 14B). These activated Ikzf1+/CD8+ T cells from the polyclonal or OT-1 system could differentiate into IFN-γ producing CTLs
with only TCR signals. This differentiation program was abrogated in the presence of neutralizing
anti-IL-2.
Ikaros expression was also characterized, and in the absence of both CD28 and cytokine
signals, wild-type naive CD8+ T cells up-regulated Ikaros more than wild-type CD8+ T cells
stimulated with TCR, CD28 and cytokine signals (Fig 14D). However, the Ikzf1+/- naive CD8+ T
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cells failed to up-regulate as much Ikaros protein expression as the wild-type cells (Fig. 14D).
Thus, like in CD4+ T cells(19), Ikaros may also act to enforce CD28 co-stimulatory signals and
cytokine signals for appropriate naive CD8+ T cell differentiation. These results will have to be
further characterized, especially due to the effects of the increase autocrine IL-2 on Ikaros
regulation and cell cycle(63) in these naïve Ikzf1+/- CD8+ T cells. Thus, appropriate Ikaros
expression is essential for ensuring that naive CD8+ T cells differentiate into highly potent
cytotoxic lymphocytes once appropriate TCR, CD28 and cytokine signals are received.
Ikaros is not up-regulated in memory CD8+ T cells upon re-stimulation
This finding that Ikzf1+/- naive CD8+ T cells can differentiate in the absence of CD28 and
cytokines signals, is similar to memory CD8+ T cell activation. Memory CD8+ T cells quickly
respond to antigen presentation in the periphery, and do not require co-stimulation or
inflammatory cytokines to rapidly induce IFN-γ, Granzyme B and Perforin(142-144). The ability of
memory cells to quickly up-regulate cytolytic factors implies that the chromatin around these
genes is more accessible in comparison to naive CD8+ T cells, which fail to produce these
factors quickly(142). Interestingly, memory CD8+ T cells have been characterized to have
increased histone acetylation(20) and partial methylation of CpGs(142) of the IFN-γ locus in
comparison to the hypoacetylated and fully methylated CpGs in naive CD8+ T cells, and quickly
lose the remaining CpG methylation upon antigen re-stimulation(142). Chromatin marks around
IFN-γ, Perforin and Granzyme B have also been characterized to be more accessible in
comparison to naive CD8+ T cells(145, 146), and this results in increased mRNA transcripts for
re-stimulated memory CD8+ T cells in comparison to stimulated naive CD8+ T cells(145). Thus,
memory Cd8+ T cells have distinct epigenetic profiles from naive CD8+ T cells, as they need to
produce lytic factors in a rapid fashion.
Due to the difference in epigenetic states of naive and memory CD8+ T cells, this hints at a
possible role for Ikaros’ function in memory CD8+ T cells. Ikaros has been characterized to
regulate the IFN-γ(86) and IL-2 loci (19, 81), and T cells with reduced Ikaros demonstrate
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increased cytokine function and more accessible chromatin around these cytokine genes (86)similar to memory T cell function.
Additionally, our experimental data with naive Ikzf1+/- CD8+ T cells has implications for
Ikaros function in memory CD8+ T cell generation. Activated naive Ikzf1+/- up-regulate Eomes
upon activation, and Eomes has been implicated in both driving the effector program(90) and
linked to memory CD8+ T cell formation (90, 147). The increased expression of CD25 by Ikzf1+/CD8+ T cells in vitro could also influence memory formation, as CD25hi CD8+ T cells could bias
toward a terminally differentiated effector phenotype at the expense of memory precursors (33,
36). Finally, the ability of naive Ikzf1+/- CD8+ T cells to differentiate in response only to TCR or
TCR/CD28 signals and produce IFN-γ and Granzyme B in a rapid fashion is very similar to
memory CD8+ T cell activation.
Finally, we have preliminary data about Ikaros expression in memory CD8+ T cells that may
indicate its role in memory function. Sorted naive (CD62L+CD44-) and memory populations
(CD44+CD62L+) from uninfected wild-type and Ikzf1+/- mice were characterized for their Ikaros
expression in unstimulated or TCR/CD28 stimulated cells (Fig. 15A). As expected, in the absence
of inflammatory cytokines, Ikaros was up-regulated in the activated naive population. However,
the activated wild-type memory cells demonstrated less Ikaros up-regulation in comparison to
their wild-type effectors (Figure 15A). Interestingly, the activated wild-type memory CD8+ T cell
population also expressed similar Ikaros levels as the activated Ikzf1+/- memory CD8+ T cells.
This may demonstrate that wild-type memory CD8+ T cells induce lower Ikaros levels in order to
quickly activate their effector program. In re-stimulation of wild-type and Ikzf1+/- memory cells, it
is readily apparent that the wild-type cells produce more IFN-γ and IL-2 in comparison to their
activated effectors (Fig 15B). Additionally, the Ikzf1+/- memory cells express more IFN-γ and IL-2
than the wild-type memory cells and further demonstrate that decreased Ikaros levels in memory
cells results in increased cytokine production. These findings needs to be further characterized,
but it is tantalizing to speculate that wild-type memory CD8+ T cells have lower Ikaros expression
in order to reduce the negative regulation that Ikaros has on the effector genes programs.
Essentially, due to the need for rapid effector gene activation in memory CD8+ T cells, it is
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possible to hypothesize that lower Ikaros expression would result in less epigenetic repression.
As Ikzf1+/- naive CD8+ T cells can differentiate into CTLs with enhanced effector function and in
similar fashion to memory CD8+ T cell re-activation, then it is plausible that there could be link to
reduced Ikaros expression and the rapid re-activation of the effector program in memory CD8+ T
cells.

Ikaros enforces the requirement for CD4+ T cell help
This preliminary data in conjunction with Chapter 2 and Chapter 3, demonstrate that Ikaros
enforces CD4+ T cell help to gain appropriate effector differentiation. The naïve Ikzf1+/- CD8+ T
cells have an increased ability in comparison to wild-type CD8+ T cells to differentiate in vitro in
the absence of CD4+ T cells and the IL-2 they provide (Fig. 3, 4). Due to their increased
autocrine IL-2 and their ability to only respond to TCR and CD28 signals, these Ikzf1+/- CD8+ T
cells can act like IL-2 producing CD4+ T helper cells. Their increased IL-2 production can act in a
paracrine fashion on wild-type naïve CD8+ T cells, and through IL-2 negative regulation of
Ikaros(82) promote the differentiation of the wild-type CD8+ T cells into IFN-γ producing CTLs
(Fig. 6). This again demonstrates the need for Ikaros to tightly restrict autocrine IL-2 production,
to ensure that naïve CD8+ T cells produce IL-2 under appropriate circumstances and prevent
paracrine IL-2 driven CD8+ T cell differentiation in a non-specific manner.
With Ikzf1+/- CD8+ T cells acting in a similar fashion as CD4+ Th cells, it is plausible that
they can bypass the need for CD4+ T cell licensing of DCs(22) or CD4+ T cell derived IL-2 (10,
11, 23) and become activated in the absence of CD4+ T cell help. The increased tumor killing by
Ikaros-modified CAR T cells in Chapter 3 may demonstrate this. In this model, no
lymphodepletion is required to create “space” for these transferred cells, which are composed of
greater than 90% CD8+ T cells. The lack of transferred CAR-specific CD4+ T cells tests the
fitness of the transferred CTLs to become activated in the absence of CD4+ T cell help. Previous
tumor models have demonstrated that paracrine IL-2 from CD4+ Th assists activated tumor
specific CTLs (95, 110) and that lymphodepletion assists adoptive T cell transfer immunotherapy
(148). Our in vivo tumor data demonstrate that the transferred Ikaros modified CAR T cells have
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enhanced in vivo killing in the absence of CD4+ help and the lack of lymphodepletion. Thus, it will
be interesting to determine if the enhanced killing by our Ikaros modified CAR-transferred CTLs in
our tumor model have increased IL-2 production and thus bypass the requirement for CD4+ T cell
help in the tumor microenvironment.

Revitalizing tumor infiltrating lymphocytes and exhausted CD8+ T cells through Ikaros modulation
Our data from the in vivo tumor models in Chapter 2 and Chapter 3 indicate that it is plausible
that controlling Ikaros’ activity represent a possible avenue for the rejuvenation of CD8+ T cell
function. In the context of the tumor microenvironment, a tumor infiltrating CD8+ T cells has to
overcome its low avidity TCR (113, 114), the lack of CD4+ T cell help(95, 110), having to
overcome engagement with negative co-stimulatory ligands (120) (119) (122) (121),
immunosuppressive cytokines and regulatory T cells (126). Additionally, a TIL activated in the
absence of CD4+ help might resemble an “unhelped” CD8+ T cells (42, 44, 103) and thus have
increased repressive marks at cytokine gene loci (20, 123). TILs isolated from tumors
demonstrate decreased responsiveness to antigen and are rejuvenated in vitro through culture in
cytokines (148) in order to utilize for adoptive cell transfer therapy.
As detailed in Chapter 3, Ikaros represents a viable target to restore CD8+ T cell effector
function. Through utilizing anti-mesothelin CARs to overcome low TCR avidity issues(115), and
expressing them in T cells that express 50-90% less Ikaros expression, these transduced T cells
are able to demonstrate enhanced anti-tumor function in vivo. Additionally, these results are not
due to differences in autocrine IL-2 production, as both wild-type and Ikzf1+/- or IkDN T cells
were initially cultured in high amounts of IL-2. This indicates that Ikaros is also regulating other
components of the CTL effector pathway, as the T cells with reduced Ikaros express more IFN-γ,
TNF-α and Granzyme B (Fig. 9). These factors are critical for anti-tumor activity and demonstrate
that by inhibition of a transcriptional repressor in CTLs, it is possible to overcome some of the
challenges associated with tumor immunotherapy.
The possibility of restoring CD8+ effector function via Ikaros modulation could also have
implications for CD8+ T cell exhaustion and chronic infections. The inability to clear virally
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infected cells by CTLs results in the persistence of antigen and chronic infections. The
persistence of antigen results in the up-regulation of multiple inhibitory receptors such as PD-1,
TIM-3, 2B4, LAG-3(144) on CD8+ T cells and results in their transition to an “exhausted” state as
they lose the ability to produce effector cytokines such as IL-2, IFN-γ, and TNF-α(144, 149).
Thus, being able to restore these antigen-specific exhausted CD8+ T cells is especially important
in the context of chronic infections like HIV. The use of anti-PD-1 antibodies has represented one
method for the restoration of effector function(150, 151), however groups have also reported on
the provision of CD4+ help(152) or the administration of exogenous IL-2 (4, 153) as possible
methods to restore the function of these exhausted CD8+ T cells. As our Ikzf1+/- CD8+ T cells
demonstrate an increased ability to produce IL-2 in comparison to wild-type CD8+ T cells
following 48 hours of chronic stimulation with plate bound anti-CD3/CD28 antibodies (Fig. 5B), it
is plausible that Ikzf1+/- CD8+ T cells could be resistant to the induction of “exhaustion”.
Introducing a P14 transgenic TCR that recognizes the LCMV-antigen gp33 onto Ikzf1+/- CD8+ T
cells (P14-Ikzf1+/-), transferring into a B6 host and then challenging with the Clone 13 strain of
LCMV to induce chronic infection, would be a viable way to test this. Thus, this increased ability
to produce autocrine IL-2 by Ikzf1+/- CD8+ T cells may present a possible pathway to preventing
exhaustion in CD8+ T cells.
Overall, these preliminary data indicate that reduced Ikaros expression can alter the
differentiation program of naïve CD8+ T cells to one that is similar to memory CD8+ T cell
activation. Additionally, the requirement to quickly respond to antigen could require inhibition of
Ikaros induction in memory CD8+ T cells and thus modulating Ikaros may represent a therapeutic
strategy to change the effector state of the CD8+ T cell.
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FIGURES

Figure	
  14:	
  Naive	
  Ikzf1+/-‐	
  CD8+	
  T	
  cells	
  can	
  differentiate	
  into	
  IFN-‐γ	
  producing	
  CTLs	
  in	
  response	
  to	
  
only	
  TCR	
  signals.
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Naive sorted wild-type (CD45.1) or Ikzf1+/-(CD45.2) CD8+ T cells were stimulated in with platebound anti-CD3 (0.5ug/ml) alone or mixed 1:1 and in the presence or absence of anti-IL-2
(10ug/ml) for 48 hours and assessed by ICS (A) or for IL-2 production by ELISA (B). Naive
purified CD8+ T cells from wild-type and Ikzf1+/- RAG OT-1 mice were stimulated in the same
fashion as in 13A, and also assessed by ICS for IFN-γ production (C). Ikaros expression in naive
sorted wild-type or Ikzf1+/- CD8+ was assessed in both unstimulated or stimulations with antiCD3 (0.5ug/ml) or anti-CD3/CD28 (0.5ug/ml) for 24 hours by Western Blot. * is p<0.05, ** is
p<0.01, and *** is p<0.001 by Student’s T-test.
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Figure	
  15:	
  Activated	
  wild-‐type	
  memory	
  CD8+	
  T	
  cells	
  express	
  less	
  Ikaros	
  in	
  comparison	
  to	
  
TCR/CD28	
  stimulated	
  wild-‐type	
  effectors	
  and	
  produce	
  more	
  IFN-‐γ+	
  and	
  IL-‐2	
  upon	
  re-‐stimulation	
  
	
  
Naive sorted cells (CD62L+CD44-) and memory CD8+ T cells (CD62L+CD44hi) cells were
isolated from wild-type and Ikzf1+/- mice and were left unstimulated or stimulated with plate
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bound anti-CD3 and anti-CD28 (1.0, 0.5ug/ml) for 48 hours. Ikaros expression was characterized
by Western Blot (A) from 0.5e6 cell equivalents. Similarly, naive, effector and central memory
CD8+ T cells were re-stimulated with PMA/I (30ng/ml, 1uM) and analyzed by ICS (B).
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In the context of naïve CD8+ T cells, they require TCR, CD28 and Signal 3 Cytokines (154)
for their appropriate differentiation into effector cells. In our in vitro priming system in Chapter 2, I
demonstrated how Ikaros protein levels are regulated by TCR, CD28 and cytokine signals. Naïve
wild-type CD8+ T cells primed with TCR, CD28 and cytokines such as IL-2 or IL-12 (Fig. 3 and 4)
failed to induce much Ikaros expression and the cells were able to differentiate into IFN-γ
producing effector cells (Fig. 4). Conversely, in the absence of IL-2 and IL-12, TCR and CD28
signals resulted in high Ikaros protein induction and the wild-type cells failed to differentiate into
CTLs. Thus, TCR and CD28 signals alone induce high amounts of Ikaros protein levels; possibly
through TCR and CD28 mediated signals that drive Ikaros transcription (Fig. 16A).
This induction of Ikaros hints at a role for Ikaros enforcing cytokine signaling to drive
appropriate naïve CD8+ T cell differentiation. With IL-2, Ikaros enforces CD8+ dependency on
CD4 help from the periphery for their differentiation. In the absence of paracrine IL-2 from
activated CD4+ T cells (11, 155), or appropriately licensed DCs that promote CD8+ production of
IL-2 via CD27-CD70 engagement(24), these wild-type CD8+ T cells fail to receive CD4+ T cell
mediated help and fail to differentiate. Additionally, our data has demonstrated for the first time
that Ikaros is regulated by IL-12, which is produced by activated DCs and again showcases a
possible link between the inflammatory environment and Ikaros regulation of the naïve CD8+ T
cell differentiation program. Reduced Ikaros expression results in increased sensitivity of the
naïve CD8+ T cells to cytokines signals(101) and helps to drive their effector function, especially
when IL-2+IL-12 combination is administered (Fig. 8). With IL-12 acting to enhance IL-2 signaling
through mediating enhanced CD25 expression (99) (100), it is possible to envision both CD4+ T
cells and inflammatory cytokines from activated dendritic cells during an anti-viral immune
response contributing to drive repression of Ikaros expression and enhanced CTL differentiation.
As Type I IFN and IL-21 have been characterized as inflammatory cytokines (40) (3), it will be
interesting to also determine if they have a similar regulatory role with Ikaros. Thus, Ikaros
enforces a dependency on cytokine signals derived from CD4+ T cells (CD4 help) or activated
DCs to ensure appropriate differentiation during an inflammatory immune response.
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In the presence of cytokine signals, it is possible that IL-2 or IL-12 signaling could act to block
the TCR/CD28 mediated transcription of Ikaros (Fig 16B) and result in decreased Ikaros protein
(Fig 3 and 4). Additionally, as Ikaros is regulated by phoshorylation (65-67), it is possible that
cytokine signaling could act via an unknown kinase to promote hyperphosphorylation of Ikaros,
and targeting it to the ubiquination pathway(67) (Fig. 16B). Ikaros degradation results in less
repression of target genes, and cytokine signaling could then promote gene expression of factors
that promote CD8+ T cell differentiation (Eomes (36) and T-bet(156)) and cell cycle progression.
Finally, cytokines signaling could induce factors that compete with Ikaros for binding at effector
gene promoters and thus inhibit Ikaros’ ability to bind to its target genes and prevent its
repressive ability. Thus, while my data indicates a role for IL-2 and IL-12 signaling in regulating
Ikaros activity in activated CD8+ T cells, there still remain many avenues to investigate in how
these cytokine signals regulates Ikaros.
This high induction of Ikaros in TCR and CD28 stimulated naïve CD8+ T cells could also
serve to prevent CD8+ T cell activation against self-antigen. When presented with foreign antigen
in an inflammatory environment (Fig. 17), the naïve CD8+ T cell has appropriate stimulus, fails to
induce much Ikaros, and can differentiate into a CTL to clear out the pathogen. However,
presentation of self-antigen in the periphery is typically done in the absence of inflammatory
signals and hence these wild-type naïve CD8+ T cells up-regulate more Ikaros and fail to
differentiate.
This ability to differentiate between self and foreign pathogen environments is especially
important for these cytotoxic CD8+ T cells, as aberrant activation can result in immunopathology.
This is apparent in cases of molecular mimicry, as viral specific CD8+ T cells that have been
previously activated by an inflammatory environment can target self-antigen that has similar
epitopes as the viral pathogen. In the RIP-LCMV model, LCMV specific CD8+ T cells can cause
murine diabetes or liver damage through targeting these organs that express gp33(157). While
the etiology is unclear, effector CTLs have been implicated in causing immunopathology
associated with type 1 diabetes (158), multiple sclerosis (159), rheumatoid arthritis (160), and
liver hepatitis(161). Thus, appropriate licensing of naïve CD8+ T cells is important to restricting
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CD8+ T cell mediated immunopathology and Ikaros up-regulation appears to play a clear role
through autocrine IL-2 restriction.
This restriction of autocrine IL-2 is especially important, as self-reactive naïve CD8+ T cells
activated in the presence of IL-2 can mediate both tumor rejection and immunopathology. In the
same transgenic system as utilized in Figure 8, the Restifo lab has demonstrated that activated
PMEL cells supplied with IL-2 can target self-antigen and cause effective anti-tumor immunity(95)
and also induce vitiligo (95, 162) and ocular autoimmunity(163). As our work has demonstrated
that IL-2 up-regulates Granzyme B in activated CD8+ T cells (Fig 7), this has implications for
immunopathology as Granzyme B+ CD8+ T cells have been associated with systemic lupus
erythematosus(164). While the Ikzf1+/- mice fail to demonstrate any signs of autoimmunity, it will
be interesting to determine if their increased autocrine IL-2 production in vivo in response to selfantigen or viral antigen could result in pathology. As exogenously supplied during the CD8+ T cell
contraction phase of an infection response results in increased viral specific CD8+ T cells(4), it
could be possible that viral specific Ikzf1+/- CD8+ T could promote inflammation through delayed
contraction. Thus, induction of Ikaros in absence of inflammatory signals represses autocrine IL2 production, and plays a critical role in preventing CD8+ T cell mediated immunopathology.
A negative of this prevention of CD8+ T cell mediated immunopathology is the challenge of
activating a self-reactive CD8+ T cells against a tumor antigen. As tumor cells express selfantigen and the tumor microenvironment contains immunosuppressive cytokines and lack CD4+
T cells(126, 165), it is possible that tumor-reactive CD8+ T cell would up-regulate Ikaros and
prevent their response to the tumor. As demonstrated in Chapter 3, using T cells with reduced
Ikaros via the Ikzf1+/- and IkDN models demonstrates that repressing Ikaros activity could
represent a possible pathway to revitalizing tumor-reactive CD8+ T cells, and possibly bypass
required CD4+ T cell help in the tumor microenvironment (95, 110). Thus, it will be interesting to
determine if poorly responsive TILs up-regulate Ikaros in response to self-antigen, and if the use
of Ikaros shRNA(19) could remove the block on differentiation.
After naïve CD8+ T cells receive appropriate differentiate signals, they can give rise to both
effectors and memory precursors(166). These memory CD8+ T cells are now antigen
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experienced and licensed to have a rapid recall response to pathogen(143). It now appears that
Ikaros also plays a role in memory CD8+ T cell biology. As outlined in Chapter 5 (Fig.16), it
appears that while quiescent wild-type memory CD8+ T cells express moderate levels of Ikaros,
they fail to induce Ikaros to the same levels as naïve CD8+ T cells following TCR and CD28
signals. While this result is preliminary, it is possibly due to increased autocrine IL-2 by memory
CD8+ T cells that IL-2 acts in a negative feedback loop on Ikaros(167). Thus, memory CD8+ T
cells may not induce as much Ikaros in order to promote their rapid differentiation into effector
cells (Fig. 17).
In summary, Ikaros is a transcription repressor that has multiple roles in CD8+ T cell biology
and its expression can influence the ability of a CD8+ T cell to respond appropriately to antigen.
While its down-regulation in response to IL-2 and IL-12 promotes appropriate CTL differentiation
and response to inflammatory stimuli, the lack of CD4 help and inflammatory signals in the tumor
microenvironment could induce its up-regulation and promote poor anti-tumor immune responses.
Ikaros acts as a sensor to ensure that the tightly regulated cytotoxic program of naïve CD8+ T
cells is appropriately released during infection and prevents aberrant immunopathology. Thus,
being able to modulate Ikaros expression could have implications for tumor immunotherapy or the
rescue of exhausted CTLs, through promoting increased autocrine IL-2 production to drive
increased CTL differentiation and bypass CD4+ T cell help.
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Figures

Figure	
  16-‐	
  Possible	
  regulatory	
  mechanism	
  of	
  Ikaros	
  
	
  
In A, TCR and CD28 signals alone act to induce Ikaros through possibly initiating Ikaros
transcription, resulting in increased Ikaros protein expression. This results in gene repression. In
the presence of CD4+ T cells and paracrine IL-2 (B), IL-2 signaling could inhibit Ikaros
transcription, promote Ikaros protein degradation and also promote factors that compete with
Ikaros at effector genes.
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Figure	
  17-‐Ikaros	
  in	
  CD8+	
  T	
  cell	
  biology	
  
	
  
In naïve CD8+ T cells, there is little active Ikaros present. Upon activation with TCR, CD28 and
inflammatory cytokines, Ikaros production is inhibited and the naïve CD8+ T cell can differentiate
into a CTL to eliminate the foreign pathogen.
Activation in the absence of inflammatory cytokines, results in induction of Ikaros and a failure of
the naïve CD8+ T cell to differentiate into an effector CTL and prevents immunopathology. This
poses a challenge in the tumor microenvironment, as CD8+ T cells fail to respond to self-antigen.
Modulating Ikaros, as in Chapter 3, results in the restoration of effector function and ability to
respond to self-antigen.
A memory Cd8+ T cell does not induce as much Ikaros as naïve CD8+ T cell and can be
activated in the absence of inflammatory signals as it only requires being activated by a recall
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antigen. The activated memory cell then can quickly differentiate and respond to the antigen of
interest. Thus, Ikaros plays a role in regulating the different activation stages of CD8+ T cell
differentiation.
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